

# UCSF

## UC San Francisco Previously Published Works

### Title

Psychedelics in developmental stuttering to modulate brain functioning: a new therapeutic perspective?

### Permalink

<https://escholarship.org/uc/item/2nw927kx>

### Authors

Pasculli, Giuseppe

Busan, Pierpaolo

Jackson, Eric

et al.

### Publication Date

2024

### DOI

10.3389/fnhum.2024.1402549

Peer reviewed



## OPEN ACCESS

## EDITED BY

Susan Jerger,  
The University of Texas at Dallas,  
United States

## REVIEWED BY

Rita Cafaro,  
University of Milan, Italy  
Anelise Junqueira Bohnen,  
Instituto Brasileiro de Fluência (IBF), Brazil  
Lisa LaSalle,  
California State University, Monterey Bay,  
United States

## \*CORRESPONDENCE

Giuseppe Pasculli  
✉ [pasculli@diag.uniroma1.it](mailto:pasculli@diag.uniroma1.it)

†These authors have contributed equally to  
this work and share first authorship

RECEIVED 17 March 2024

ACCEPTED 27 May 2024

PUBLISHED 19 June 2024

## CITATION

Pasculli G, Busan P, Jackson ES, Alm PA,  
De Gregorio D, Maguire GA, Goodwin GM,  
Gobbi G, Erritzoe D and Carhart-Harris RL  
(2024) Psychedelics in developmental  
stuttering to modulate brain functioning:  
a new therapeutic perspective?  
*Front. Hum. Neurosci.* 18:1402549.  
doi: 10.3389/fnhum.2024.1402549

## COPYRIGHT

© 2024 Pasculli, Busan, Jackson, Alm, De  
Gregorio, Maguire, Goodwin, Gobbi, Erritzoe  
and Carhart-Harris. This is an open-access  
article distributed under the terms of the  
[Creative Commons Attribution License  
\(CC BY\)](https://creativecommons.org/licenses/by/4.0/). The use, distribution or reproduction  
in other forums is permitted, provided the  
original author(s) and the copyright owner(s)  
are credited and that the original publication  
in this journal is cited, in accordance with  
accepted academic practice. No use,  
distribution or reproduction is permitted  
which does not comply with these terms.

# Psychedelics in developmental stuttering to modulate brain functioning: a new therapeutic perspective?

Giuseppe Pasculli<sup>1,2\*†</sup>, Pierpaolo Busan<sup>3†</sup>, Eric S. Jackson<sup>4</sup>,  
Per A. Alm<sup>4,5</sup>, Danilo De Gregorio<sup>6,7</sup>, Gerald A. Maguire<sup>8,9</sup>,  
Guy M. Goodwin<sup>10</sup>, Gabriella Gobbi<sup>11</sup>, David Erritzoe<sup>12</sup> and  
Robin L. Carhart-Harris<sup>12,13</sup>

<sup>1</sup>Department of Computer, Control, and Management Engineering (DIAG), La Sapienza University, Rome, Italy, <sup>2</sup>Italian Society of Psychedelic Medicine (Società Italiana di Medicina Psichedelica—SIMEpsi), Bari, Italy, <sup>3</sup>IRCCS Ospedale San Camillo, Venice, Italy, <sup>4</sup>Department of Communicative Sciences and Disorders, New York University, New York, NY, United States, <sup>5</sup>Department of Public Health and Caring Sciences, Uppsala University, Uppsala, Sweden, <sup>6</sup>IRCCS, San Raffaele Scientific Institute, Milan, Italy, <sup>7</sup>Vita-Salute San Raffaele University, Milan, Italy, <sup>8</sup>School of Medicine, American University of Health Sciences, Signal Hill, CA, United States, <sup>9</sup>CenExel CIT Research, Riverside, CA, United States, <sup>10</sup>Department of Psychiatry, University of Oxford, Oxford, United Kingdom, <sup>11</sup>Neurobiological Psychiatry Unit, Department of Psychiatry, McGill University, Montreal, QC, Canada, <sup>12</sup>Department of Medicine, Centre for Psychedelic Research, Imperial College London, London, United Kingdom, <sup>13</sup>Psychedelics Division, Neuroscape, University of California, San Francisco, CA, United States

Developmental stuttering (DS) is a neurodevelopmental speech-motor disorder characterized by symptoms such as blocks, repetitions, and prolongations. Persistent DS often has a significant negative impact on quality of life, and interventions for it have limited efficacy. Herein, we briefly review existing research on the neurophysiological underpinnings of DS—specifically, brain metabolic and default mode/social-cognitive networks (DMN/SCN) anomalies—arguing that psychedelic compounds might be considered and investigated (e.g., in randomized clinical trials) for treatment of DS. The neural background of DS is likely to be heterogeneous, and some contribution from genetically determinants of metabolic deficiencies in the basal ganglia and speech-motor cortical regions are thought to play a role in appearance of DS symptoms, which possibly results in a cascade of events contributing to impairments in speech-motor execution. In persistent DS, the difficulties of speech are often linked to a series of associated aspects such as social anxiety and social avoidance. In this context, the SCN and DMN (also influencing a series of fronto-parietal, somato-motor, and attentional networks) may have a role in worsening dysfluencies. Interestingly, brain metabolism and SCN/DMN connectivity can be modified by psychedelics, which have been shown to improve clinical evidence of some psychiatric conditions (e.g., depression, post-traumatic stress disorder, etc.) associated with psychological constructs such as rumination and social anxiety, which also tend to be present in persistent DS. To date, while there have been no controlled trials on the effects of psychedelics in DS, anecdotal evidence suggests that these agents may have beneficial effects on stuttering and its associated characteristics. We suggest that psychedelics warrant investigation in DS.

## KEYWORDS

developmental stuttering, psychedelic compounds, neuropsychopharmacology, default mode network, social-cognitive networks

## Introduction

Developmental stuttering (DS), also known as Childhood-Onset Fluency Disorder (American Psychiatric Association, 2013), is a neurodevelopmental disturbance characterized by speech and motor symptoms including repetition, halting, and prolonging of syllables (Bloodstein et al., 2021). In addition, language processing may be affected to some extent (both in childhood and adulthood; e.g., Weber-Fox et al., 2013; Gastaldon et al., 2023). Thus, DS is a complex and multifactorial impairment where speech-motor difficulties often negatively impact the quality of life of persons who stutter (PWS), resulting in a series of associated symptoms including anxiety and social avoidance (especially in “persistent” DS; Menzies et al., 1999; Iverach et al., 2011; Iverach and Rapee, 2014). On the other hand, when stuttering begins in adulthood, it is usually the consequence of a brain injury (neurogenic stuttering; Junuzovic-Zunic et al., 2021). Recent work is clarifying the brain dynamics of DS using neuroimaging and neurophysiological methods: indeed, stuttering is thought to be a speech-motor issue related to basal ganglia dysfunction and impairments of speech/motor cortical areas, also resulting in atypical neural connectivity (Etchell et al., 2018). Thus, while there are many unanswered questions regarding the underlying neural basis of DS, a common perspective is that stuttering is associated with altered brain regulation of motor sequencing and timing of volitional control of speech (Craig-McQuaide et al., 2014; Etchell et al., 2014, 2015, 2018; Busan et al., 2019, 2020; Busan, 2020; Chang and Guenther, 2020; Tendra et al., 2020; Alm, 2021b; Gastaldon et al., 2023; Orpella et al., 2024). Nevertheless, stuttering remains difficult to treat and no resolute treatment is available, especially when it persists in adulthood. Speech therapy is the most commonly used treatment, but relapse is common (Qureshi et al., 2021). Neuromodulation and pharmacology are also increasingly investigated (for recent reviews see Maguire et al., 2020; Busan et al., 2021; Qureshi et al., 2021; see also Chesters et al., 2018, Garnett et al., 2019; Busan et al., 2023). For example, experimental pharmacological interventions in DS modulate the (nigro-striatal) dopaminergic system of the brain, typically by means of dopamine antagonists (e.g., at D2 [risperidone or olanzapine] and D1 receptors [ecopipam]; Maguire et al., 2020). In this context, serotonergic (e.g., paroxetine) or GABAergic (e.g., pagoclone) interventions have also been investigated (Maguire et al., 2020).

Recently, psychedelic drugs (i.e., serotonergic agonists producing psychedelic effects) have sparked significant interest due to their potential therapeutic effects on psychiatric conditions such as depression, (social) anxiety, and post-traumatic stress disorder (PTSD; Luoma et al., 2020; Inserra et al., 2021a). Moreover, they are also under evaluation for movement disorders such

as Parkinson’s disease (Wolff et al., 2023). Classic psychedelic drugs (e.g., psilocybin, lysergic acid diethylamide [LSD], and dimethyltryptamine [DMT]) have high affinity for the 5-HT<sub>2A</sub> serotonin receptor, but their mechanisms of action remain unclear and/or heterogenous (Moujaes et al., 2023). However, these drugs may be able to facilitate acute periods of psychological/cognitive flexibility that may promote neural plasticity that aids in changing behavioral “maladaptive” patterns (e.g., Carhart-Harris and Friston, 2019). In this regard, this perspective article puts forth the idea that psychedelic drugs might complement existing behavioral therapies, with potential fluency-facilitating effects and contributing to reduced psychosocial impact (e.g., anxiety and social avoidance), thus improving the quality of life of PWS (compare with Jackson et al., 2024). Herein, we will describe the (heterogeneous) neural and psychological background factors related to DS, as well as their possible interactions with mechanisms hypothesized for psychedelic drugs. Finally, a rationale for applying this class of drugs in DS will be proposed. For the sake of brevity, we do not make an overt distinction between data obtained from different cohorts (e.g., adult vs. children who stutter, human vs. animal models, clinical vs. pre-clinical data, different compounds, etc.) and the reader is addressed to additional references for further in-depth analyses.

## The neurophysiological basis of DS: brief overview of the current state

### Background factors

At the neurobiological level, two main themes emerge in the current research: (i) the possible role of dopamine in stuttering, and (ii) indications that stuttering may be related to impaired supply of energy to neurons (e.g., sub-optimal glycolysis processes; Wu et al., 1997; Alm, 2004, 2021a,b; Civier et al., 2013; Chang and Guenther, 2020; Chow et al., 2020; Maguire et al., 2021; Turk et al., 2021). It has been speculated that both these mechanisms might be related to genetically determined cellular metabolic limitations (especially in frontal lobe) that become evident during speech, since it may be the most energy-demanding motor task (Alm, 2021a; compare with Civier et al., 2013; Chang et al., 2019; Chang and Guenther, 2020). Cellular structures such as astrocytes and lysosomes can be also affected, thus playing a possible role in the etiopathogenesis of DS (e.g., Kang et al., 2010; Kang and Drayna, 2012; Han et al., 2019; Benito-Aragón et al., 2020; Chow et al., 2020; Maguire et al., 2021; Turk et al., 2021). Notably, studies such as that by Kraft and Yairi (2012) have highlighted a major genetic influence in the etiology of stuttering. The most compelling evidence so far points to a group of genes that are integral to intra-cellular transport and recycling processes in lysosomes, as elucidated by Barnes et al. (2016) and Frigerio-Domingues and Drayna (2017). Among these, *GNPTAB* and associated genes are instrumental in lysosomal function by affecting the trafficking of hydrolase enzymes to lysosomes. In fact, under normal conditions, *GNPTAB* is involved in synthesizing mannose 6-phosphate, a key element for directing hydrolase enzymes to lysosomes. Mutations in *GNPTAB* disrupt this essential process, thus leading to improper or insufficient delivery of these enzymes. This disruption may result in a marked deficiency

Abbreviations: DS, developmental stuttering; PWS, persons who stutter; PTSD, post-traumatic stress disorder; LSD, lysergic acid diethylamide; DMT, dimethyltryptamine; PANDAS, pediatric autoimmune neuropsychiatric disorders associated with streptococcal infections; fMRI, functional magnetic resonance imaging; DMN, default mode network; EEG, electroencephalography; SCN, social-cognitive network; SN, salience network; TPNs, task-positive networks; CEN, central executive network; BDNF, brain-derived neurotrophic factor; PK, pharmacokinetic; PD, pharmacodynamic; SAD, social anxiety disorder; RCTs, randomized clinical trials; FDA, Food and Drug Administration.

of functional hydrolases in the lysosomes, thereby hampering the degradation of glycoproteins and glycolipids. The resultant accumulation of undegraded substrates in the lysosomes can in turn impact cellular functions and contribute to the pathophysiology of DS (Alm, 2021a). Moreover, mutations in the *GNPTAB* gene may result in a reduced number of astrocytes, especially when considering structures such as the corpus callosum, which is fundamental for inter-hemispheric communication (and, thus, for speech and/or vocalization; Han et al., 2019).

On the other hand, when it comes to non-genetic factors, a recent analysis has provided evidence that streptococcal infections appear to have been a major cause of stuttering before penicillin became available by triggering an autoimmune reaction that may have affected the basal ganglia (i.e., pediatric autoimmune neuropsychiatric disorders associated with streptococcal infections [PANDAS]; Alm, 2020). Nonetheless, it is important to emphasize that the stuttering group is likely to be heterogeneous from a neurobiological perspective (e.g., when considering individual differences in responses to dopaminergic drugs; Alm, 2004, section 6.1.2).

## Neurological mechanisms

From a neural point of view, many theories of stuttering focus on the role of motor timing or on other aspects of speech-motor sequencing (Van Riper, 1982; Alm, 2004, 2021b; Etchell et al., 2014, 2015; Busan et al., 2019, 2020; Busan, 2020; Chang and Guenther, 2020; Jenson et al., 2020; Tendra et al., 2020). As a corollary, DS seems to be a disorder characterized by impairments in cortico-basal-thalamo-cortical networks (crucial for implementing and executing voluntary motor sequences, such as those needed for speech; Alm, 2004; Civier et al., 2013; Craig-McQuaide et al., 2014; Etchell et al., 2014, 2015, 2018; Busan, 2020; Chang and Guenther, 2020; Figure 1A). Structural and functional abnormalities are evident in cortical and sub-cortical regions (and their connections) including the supplementary motor area, inferior frontal regions, temporal cortex, sensorimotor cortex, basal ganglia, and the connecting white matter tracts (Sommer et al., 2002; Watkins et al., 2008; Craig-McQuaide et al., 2014; Neef et al., 2015, 2016, 2018a,b, 2022, 2023; Kronfeld-Duenias et al., 2016; Etchell et al., 2018). In this context, a very recent meta-analysis confirmed that DS is characterized by structural/functional alterations in wider brain networks, including cortico-cortical and sub-cortical circuits, that support speech fluency and motor sequences (Matsuhashi et al., 2023). These alterations may differently sustain “trait” and “state” stuttering (Budde et al., 2014; Belyk et al., 2015, 2017; Connally et al., 2018).

## A role for the default mode network in DS?

Functionally, the brain of PWS is characterized by atypical neural activity during speech-motor programming and execution, but also during rest (for a recent review see Etchell et al., 2018). For example, using functional magnetic resonance imaging (fMRI) during resting conditions, Desai et al. (2017) reported reduced




FIGURE 1

Neural pathways involved in DS, and possible interactions with psychedelics effects. (A) A prototypical representation of the (sensorimotor) cortico-basal-thalamo-cortical circuit (CBCT), which has a role in DS neuropathology, and includes regions such as the premotor cortex, supplementary motor area, thalamus, and basal ganglia (bilaterally, in yellow on an inflated model; note that basal ganglia and thalamus are schematically superimposed only for descriptive purposes); (B) a prototypical representation of the default mode network (DMN), hypothesized to have a role in DS neuropathology as well as hypothesized to be a primary neural target of psychedelics; DMN comprises regions such as the prefrontal cortex, temporal cortex, parietal cortex, and posterior cingulate cortex (bilaterally, in yellow on an inflated model); (C) a prototypical representation of a social-cognitive network (SCN; based on Amodio and Frith, 2006; compare with Alm, 2014), which has an influence on the symptoms of DS; SCN comprises prefrontal regions, also influencing functionality of the anterior cingulate cortex and the motor cortex (e.g., supplementary motor area; all regions are shown in yellow on an inflated model); (D) a prototypical representation of the saliency network (SN), which is useful for switching from DMN to TPNs, and comprises bilateral regions such as the anterior cingulate cortex and insula (in yellow on an inflated model); (E) a prototypical representation of the central executive network (CEN; as part of task-positive networks, TPNs), comprising regions such as the dorsolateral prefrontal cortex and parietal cortex (bilaterally, in yellow on an inflated model).

blood perfusion of speech-motor areas in DS. In another study, Xuan et al. (2012) suggested the presence of abnormal neural activity and functional connectivity in a series of resting-state networks, also comprising sensorimotor regions and nodes of the default mode network (DMN; Figure 1B). The DMN is a group of interconnected brain regions (mainly comprising nodes such as the prefrontal cortex, lateral/inferior parietal cortex, temporal cortex, and the posterior cingulate cortex; Andrews-Hanna et al., 2014) characterized by high basal metabolism, perfusion, small world architecture, and functional and geodesic distance from the “unimodal” cortex (Raichle, 2015). The DMN tends to show a dip



in activity when the brain is actively involved in “goal-oriented” task execution (despite a growing amount of data highlighting a key role of the DMN in itinerant, semantically abstract, internally-directed and/or self-generated/self-referential cognition; [Andrews-Hanna et al., 2014](#); [Raichle, 2015](#)). As a consequence, there is orthogonality (if not functional antagonism to the DMN) in the so-called task-positive networks (TPNs) that, for example, are activated during attention-demanding tasks in interaction with external cues ([Raichle et al., 2001](#); [Hamilton et al., 2011](#)). In fact, the DMN has high basal activity but is typically most activated when attention is not directed toward an external stimulus (e.g., during excessive rumination, which is a common condition in anxiety and depressive disorders; [Hamilton et al., 2011](#); [Fernandes Coutinho et al., 2016](#)). Interestingly, there are indications that the DMN has a role in speech disorders, such as the presence of higher connectivity between the DMN and fronto-parietal networks ([Cai et al., 2024](#)), as well as in DS pathophysiology ([Chang et al., 2018](#); [Garnett et al., 2022](#)). More specifically, [Chang et al. \(2018\)](#) reported the presence of a resting-state aberrant network connectivity in PWS, involving DMN regions (such as the posterior cingulate cortex) and their connectivity with a series of intrinsic circuits such as those related to attention, somato-motor, and fronto-parietal networks. These altered connectivity patterns predicted stuttering persistence (vs. recovery). Findings suggest that developmental alterations in the balance between functional neural networks (e.g., “lack of balance” in how attention processes regulate speech-motor control) may be important in relation to the development, appearance and/or maintenance of stuttering ([Chang et al., 2018](#)). In fact, based on this evidence, the DMN may interfere with the correct/timed recruitment of “goal-oriented” behaviors and TPNs, resulting clinically evident especially during speech and dysfluencies. In this regard, [Garnett et al. \(2022\)](#) found that PWS tend to exhibit heightened connectivity between the left superior temporal cortex (auditory regions) and regions of the DMN during “solo” speech tasks, again suggesting the existence of a possible interference exerted by the DMN during speech in PWS.

In this context, other than fMRI studies, useful evidence about resting-state neural activity may also be obtained by electroencephalography (EEG). In this case, available studies ([Finitzo et al., 1991](#); [Ozge et al., 2004](#); [Joos et al., 2014](#); [Saltuklaroglu et al., 2017](#)) mainly suggest a tendency toward reduced power of the beta band (i.e., 13–30 Hz) in PWS. Furthermore, analysis of brain connectivity based on frequency bands indicates some anomalies of resting-state activity in DS ([Joos et al., 2014](#); [Ghaderi et al., 2018](#)). Speculatively, the presence of an evident reduction in beta EEG power at rest in the brain of PWS could suggest the presence of reduced cerebral metabolism, possibly in relation to limitations in the supply of energy to neurons (e.g., sub-optimal glycolysis processes; [Alm, 2021a](#)).

In summary, some abnormalities related to (persistent) DS may be present well before the development of evident deficits in speech-motor programming and execution, likely influencing neural processing, and confirming that DS may be a more “general” disturbance than previously considered (i.e., not exclusively related to speech; [Ludlow and Loucks, 2003](#); [Busan et al., 2013, 2017](#)). Importantly, as described in the next sections, these systems may be further influenced by the presence of added “neural noise,” such as that induced by excessive anxiety. A better comprehension

of these mechanisms may furnish new suggestions for improved interventions in (persistent) DS.

## Interactions between atypical neural systems in DS and associated psychological/psychiatric characteristics: anxiety and stuttering

A common associated characteristic of (persistent) DS is the development of social anxiety, social phobia, and avoidance behaviors ([Menzies et al., 1999](#); [Iverach et al., 2011](#); [Iverach and Rapee, 2014](#)). PWS may also develop a stigmatized identity that contributes to avoidance, shame, and fear of speaking ([Sisskin and Goldstein, 2022](#)) which, in turn, might considerably impact their quality of life ([Craig et al., 2009](#); [Nang et al., 2018](#)). It is now quite clear that an emotive/emotional difference is not the fundamental driving force behind development of stuttering in children ([Reilly et al., 2009](#); [Alm, 2014](#); [Park et al., 2021](#); [Delpeche et al., 2022](#)). However, it is common that (persistent) stuttering results in association with some types of psychological profiles during school age or later ([Iverach et al., 2009](#); [St Clare et al., 2009](#); [Iverach and Rapee, 2014](#)). For example, social anxiety and unhelpful thoughts can develop into a major problem for PWS: these aspects have become the focus of specific treatment efforts, such as cognitive-behavioral therapy ([Lowe et al., 2021](#)), mindfulness ([Emge and Pellowski, 2019](#)), and, very recently, even computer/internet-based ([Gunn et al., 2019](#); [Menzies et al., 2019](#)) and virtual reality approaches ([Chard et al., 2023](#)).

Accordingly, starting from the evidence of a more “vulnerable” speech-motor system in DS ([Perkins et al., 1991](#); [Ludlow and Loucks, 2003](#); [Alm, 2004](#); [Namasivayam and van Lieshout, 2011](#); [Civier et al., 2013](#); [Craig-McQuaide et al., 2014](#); [Smith and Weber, 2017](#); [Etchell et al., 2018](#); [Busan, 2020](#); [Chang and Guenther, 2020](#)), [Alm \(2014\)](#) hypothesized that stuttering may be worsened by interference from “social cognition,” whereby the speaker’s perceptions of the listener or themselves burden an already vulnerable speech-motor control system, as a likely result of “maladaptive” processes. In fact, propositional (i.e., spontaneous) speech may be more affected in DS (as already suggested in [Eisenson and Horowitz, 1945](#)) and supported by regions such as the prefrontal cortex, supplementary motor area, basal ganglia, and the inferior frontal gyrus (see, for a perspective in DS, [Chang and Guenther, 2020](#); [Neef and Chang, 2024](#)). However, a social-cognitive network (SCN, [Figure 1C](#)) including the medial prefrontal cortex and the anterior cingulate cortex (and, hence, also comprising regions of the DMN; adapted from [Amodio and Frith, 2006](#); compare with [Wu et al., 1995](#); [Moran et al., 2006](#); [Alm, 2014](#); [Craig-McQuaide et al., 2014](#)) is also present and mainly related to the processing of socially relevant information (in this case, perhaps also exchanging information with limbic regions; see [Neef and Chang, 2024](#)). A similar view is also proposed by other recent theories and visions about DS, supporting relevant suggestions about the effects of factors such as (inefficient) speech/language processing, monitoring, time pressure, physiological arousal, temperament, and/or emotional

regulation (e.g., anxiety and fear) on speech-motor control systems (Perkins et al., 1991; Healey et al., 2004; Conture et al., 2006; Bloodstein and Ratner, 2008; Namasivayam and van Lieshout, 2011; Packman, 2012; Walden et al., 2012; Arenas, 2017; Smith and Weber, 2017). These processes also possibly involve (variable) changes in autonomic functions (see, for a brief review on DS, Garcia-Barrera and Davidow, 2015). Specifically, in the context of stuttering, social cognition may involve thoughts about oneself (e.g., negative evaluation) or concerns regarding the current speech situation, always in relation to main factors such as: (i) the importance or possible consequences of the situation; (ii) the possibility of stuttering; and (iii) the uncertainty about the best way to act (e.g., in order to avoid dysfluencies; Alm, 2014). Interestingly, this system also partially overlaps with regions of the salience network (SN, Figure 1D; Sridharan et al., 2008) that are useful for detecting or integrating sensorial (and emotional) stimuli, but also constituting a likely “switching” between DMN and networks useful for “externally-directed” cognition (Sridharan et al., 2008).

In this context, during “goal-directed” behavior (i.e., speech), the neural networks so far described are collaborating, trying to avoid (mutual) interferences (see, for a perspective on DS, Alm, 2014). As anticipated, the SN may facilitate the capacity to switch between the DMN (as already suggested, usually related to the resting condition and introspection) and TPNs such as the executive control networks (e.g., the central executive network, CEN; Gratton et al., 2018; Figure 1E). In fact, TPNs usually need attention that is focused on external cognitive or motor tasks (Corbetta and Shulman, 2002; Kincade et al., 2005), thus recruiting regions such as the insula and the frontal operculum, the supplementary motor cortex, the medial frontal lobe, the lateral premotor cortex, and the middle frontal gyrus, as well as the superior/inferior parietal lobule and posterior temporal gyri (Blumenfeld, 2016). Interestingly, most of these networks (i.e., SCN, DMN, and SN) have been suggested to have a role in negative reactions to stuttering, thus likely contributing to the development of social anxiety (Alm, 2014). As in a vicious circle, this anxiety is reinforced by the anticipation of stuttering which increases in extent and complexity throughout development (Jackson et al., 2015, 2018, 2019; Rodgers and Jackson, 2021), thus possibly resulting in further repetitive and negative thinking or rumination (Tichenor and Yaruss, 2020). Interestingly, Orpella et al. (2024) suggest that this may result in a further abnormal involvement of control on processes during speech production, especially prior to anticipated and stuttered (vs. fluent) speech (Jackson et al., 2022). In this regard, it has been suggested that internally-(vs. externally-)directed focus may contribute to disrupt simple/automatic movements (Wulf et al., 2001; McNevin et al., 2003; Kal et al., 2013), also in DS (e.g., Eichorn et al., 2016, 2019; Jackson et al., 2016).

A striking characteristic of stuttering is its typical variability in most cases, between situations and from moment to moment (Constantino et al., 2016; Tichenor and Yaruss, 2021), also as a function of audience (Jackson et al., 2016). In this context, Jackson et al. (2021) showed that, in DS, disfluencies are virtually eliminated during “private” speech (i.e., speaking “alone” condition). Again, this evidence relates with the capacity of PWS to anticipate their stuttering (Brocklehurst et al., 2013; Garcia-Barrera and Davidow, 2015; compare with Bloodstein, 1975; Arenas, 2017):

conditions of stuttering anticipation are related to consistent overactivation of the right prefrontal cortex (Jackson et al., 2022). During “private” speech there would be no social evaluation, communicative aim, or the need to interpret listener information, thereby reducing potential interferences from the SCN/DMN on an already vulnerable speech-motor system (Alm, 2014, section 8.5; Smith and Weber, 2017). Thus, the difference between talking alone and talking to someone else appears to be sufficient to result in speech disruptions for PWS. Alm (2014) proposed that the SCN/DMN tends to interfere with the TPNs during social situations, thus triggering stuttering (a similar view of the role of DMN in DS was put forward in Chang et al., 2018). According to the proposed model, it can be expected that social anxiety and activation of the DMN will result in suppression of speech-motor related networks, thereby increasing the risk for stuttering (Walden et al., 2012; Brocklehurst et al., 2013; Alm, 2014; Smith and Weber, 2017).

In this regard, stuttering events seem to correlate with the presence of higher inhibitory activity in sensorimotor networks (Korzeczek et al., 2022; Orpella et al., 2024). In this case, evidence suggests that “maladaptive” processes, also involving the above-described patterns and, possibly, abnormal modulation of action-stopping networks (Neef et al., 2018a, 2022, 2023; Busan et al., 2020; Korzeczek et al., 2022), may have a role in interaction with circuits involved in emotion regulation (Neef et al., 2018b, 2022, 2023; Montag et al., 2019; Chow et al., 2023). Indeed, recent research (Yang et al., 2017; Toyomura et al., 2018) showed the presence of neurophysiological connections between emotional regulation and stuttering. For example, activity in the right amygdala (a key anatomical region in the limbic system involved in fear responses and emotions elaboration; Šimić et al., 2021) was correlated with disfluencies and discomfort in PWS, also influencing activity in the prefrontal cortex (which is part of an emotion-regulation system with the amygdala; Toyomura et al., 2018). Similarly, during a speech task, PWS showed increased functional connectivity of the right amygdala with prefrontal regions and the left insula (Yang et al., 2017). During resting-state conditions, PWS also showed stronger connectivity between the hippocampus and prefrontal/motor areas. In summary, the available evidence suggests that aberrant neural activity for anxiety regulation might have a role in the higher levels of anxiety observed in DS, possibly also in relation to stuttering severity. As a consequence, attention of PWS could be mainly “internally” focused (i.e., likely on the possible social consequences of stuttering), rather than being on the interlocutor.

All things considered, a potential rationale for the usage of psychedelics in DS will be developed in the next sections. There are several pre-clinical and clinical indications that psychedelics (e.g., LSD) may have a therapeutic role in alleviating anxiety (see, for a recent review, Insera et al., 2023). Thus, by reducing anxiety in DS, psychedelics may modulate activity in overactivated (or underactivated) systems, thereby reducing difficulties and allowing “easier” control (i.e., with limited interferences) of speech-motor systems (Alm, 2014; Jackson et al., 2022; Orpella et al., 2024). The mechanisms could be through effects on brain metabolism and their capacity to promote plasticity, also in networks such as the SCN/DMN and emotional regulatory systems (compare with Ly et al., 2018).

## Psychedelic drugs: possible brain mechanisms

Drugs producing psychedelic experiences are mainly known to act via 5-HT<sub>2A</sub> receptor agonism, even if the agonism and/or partial agonism of receptors such as 5-HT<sub>1A</sub>, 5-HT<sub>7</sub>, and D<sub>2</sub> also play an important role (Inserra et al., 2021a; Ling et al., 2022). 5-HT<sub>2A</sub> receptor agonism indirectly induces glutamate release, for example by activating AMPA receptors (Aghajanian and Marek, 1997; De Gregorio et al., 2021). The activation of AMPA and glutamatergic systems is likely linked to the neuronal plasticity of brain regions such as the hippocampus, amygdala, and prefrontal cortex, even if more studies are needed to demonstrate a direct link (Ly et al., 2018; Inserra et al., 2021a). It has been recently suggested that the effects of this class of drugs on neurotrophic signals and plasticity may also depend on the binding of the brain-derived neurotrophic factor (BDNF) receptor TrkB, which is useful in promoting endogenous BDNF signaling (see Moliner et al., 2023). However, since antidepressant drugs (e.g., selective serotonin reuptake inhibitors) also increase BDNF (even if psychedelics would have higher affinity), it is difficult to understand if this could be specific to psychedelics or a common mechanism for antidepressant drugs (Saarelainen et al., 2003). At regular/high doses, psychedelics produce an experience with vivid hallucinations and mind alteration, and may also induce profound psychological and “mystical” experiences (Griffiths et al., 2008; Hirota and Lambert, 2022; Vamvakopoulou et al., 2023). In this context, psychedelic drugs such as psilocybin may elicit a subjective state that could be described as “a waking dream,” where memory formation and insights usually remain intact, but the nature and range of consciously experienced mental processes are broad and shifted toward “imprecision” (relative to normal consciousness). More specifically, sensory distortions, strong emotions, phantasmagoria, and blurring of conceptual boundaries are common and dose-dependent. Sensations of “bliss,” “elemental imagery,” “experience of unity,” “spiritual experience,” “insightfulness,” “audio-visual synesthesia,” and others are also usually very frequently reported under psilocybin. However, since psychedelic drugs may also be viewed as non-specific amplifiers of mental processes, the range and degree of reported experiences also includes negative ones such as panic, paranoia, and hallucinations (Rucker and Erritzoe, 2023). In this context, the safety of psychedelics is contingent upon dosage, with psychological adverse events usually predominating over physiological ones. The pharmacokinetics (PK) of psychedelics is complex, and each drug has a distinct profile. For example, LSD (200 µg) has a plasma half-life of 2.5 h, but the hallucinogenic effect is long-lasting (about 12 h; see Dolder et al., 2017). On the other hand, psilocybin is rapidly converted in psilocin after oral ingestion by plasmatic and hepatic enzymes, and elimination half-life is about 1.4 h. On the other hand, DMT is not bio-available and should be administered in humans by slow intravenous infusion, obtaining rapid attainment of peak plasma concentrations followed by rapid clearance (Good et al., 2023). When considering the pharmacodynamics (PD) of psychedelics, it is not directly associated with PK: for example, for LSD, the effects on anxiety are detectable after a few days and may persist for weeks (Holze et al., 2023). This peculiar PD is likely related to neuroplastic and/or epigenetic modulations induced by

psychedelics and, thus, to their effects on neural circuits (Inserra et al., 2021a).

When combined with psychological support/therapy (Fuentes et al., 2020; Gobbi et al., 2022; Lowe et al., 2022), the therapeutic effects of psychedelics for mental diseases like major and resistant depression (Carhart-Harris et al., 2021; Goodwin et al., 2022), anxiety (Gasser et al., 2014, 2015; Holze et al., 2023), and alcohol use disorder (Bogenschutz et al., 2022) are highly promising, even if one cannot rule out the essential role of psychotherapy in the reappraisal of negative biases after the psychedelic experience. Undoubtedly, more studies are required to understand these links. Consistently, in animals it has been demonstrated that psychedelics, such as LSD, may reduce stress-induced anxiety through serotonergic mechanisms: during stress, the firing activity of 5-HT neurons in the dorsal raphe is decreased, but chronic administration of LSD may restore a more physiological activity through desensitization of 5-HT<sub>1A</sub> auto-receptors (De Gregorio et al., 2022). Moreover, LSD treatment (i.e., 30 µg/kg once a day for 7 days) allows spinogenesis to increase (see De Gregorio et al., 2021, 2022), and, in parallel, promotes the methylation of genes involved in neuroplasticity processes of brain regions such as the prefrontal cortex (Inserra et al., 2022). However, further studies are required to better understand if epigenetic processes like hypermethylation/hypo-methylation are directly linked to spinogenesis, or if spinogenesis is independent from epigenetic mechanisms. Interestingly, it has also been proposed that psychedelics can evoke “metaplasticity,” a phenomenon making neurons more susceptible to stimuli that induce plasticity (e.g., hormones, neurotrophic factors, etc.; Nardou et al., 2023): this is compelling for DS, since it may involve reshaping of neurons and networks that may be dysfunctional in stuttering.

In this context, more work is needed to understand how the increased neural plasticity induced by psychedelics (see Calder and Hasler, 2023) is linked to the changes in brain circuitry and increase in “entropy” of neural networks (Carhart-Harris and Friston, 2019; Inserra et al., 2021a; Herzog et al., 2023; Ort et al., 2023; Wall et al., 2023). The “acute” and “rebound” activity could be in opposite directions when considering brain metabolism (see Vollenweider et al., 1997; Carhart-Harris et al., 2012). For example, psilocybin seems to result in a rapid decrease in activity of hub regions (such as the thalamus or the anterior/posterior cingulate regions; Carhart-Harris et al., 2012), possibly followed in time by an increase in brain metabolism of frontal regions (Vollenweider et al., 1997; see Lewis et al., 2017, for a discussion combining “hyper-frontal” hypotheses of psilocybin with studies demonstrating a more general decrease in brain perfusion). Moreover, psychedelics seem to “disrupt” connectivity, especially in resting-state networks such as the DMN, also resulting in induced modifications of the functional connectivity between these circuits and other brain networks (Carhart-Harris et al., 2013, 2017; Daws et al., 2022; Felsch and Kuypers, 2022) that, for example, may favor “goal-directed” behaviors. In this context, a series of different models have been proposed that attempt to explain the various effects of doses of psychedelic drugs on the brain, also making assumptions about their induced neural modulations (e.g., DMN; Carhart-Harris and Friston, 2019; Vollenweider and Preller, 2020; Daws et al., 2022; Doss et al., 2022; Gattuso et al., 2023; Herzog et al., 2023; Wall et al., 2023). Nonetheless, it is still not clear what is the main brain target of the therapeutic potential of, for example, psilocybin



(Gattuso et al., 2023). A recent systematic review by Gattuso et al. (2023) constituted further evidence in favor of the idea that the DMN may be linked to effects such as “ego dissolution,” enhanced mental health, and wellbeing (Carhart-Harris et al., 2014; Nour et al., 2016). In this context, recent studies indicate that the effects may be related to the modulation of functional connectivity between networks, rather than within them (see Gattuso et al., 2023; compare with Tagliazucchi et al., 2016; Girn et al., 2022). This can mean that brain areas which typically have strong functional connections may be not further and mutually reinforced but, on the other hand, brain areas whose activity is only “weakly” correlated may tend to become more connected (see Gattuso et al., 2023; compare with Tagliazucchi et al., 2016; Girn et al., 2022). Some evidence suggests that diffuse effects (i.e., up-regulation of c-FOS, a marker of neuroplasticity processes) on sensorimotor circuits and association regions, as well as on anterior cingulate cortex and sub-cortical regions is present (such as the thalamus and the amygdala; see Davoudian et al., 2023; compare with Calder and Hasler, 2023). In particular, sensorial or “gating” structures, such as the thalamus (or associated structures, such as the claustrum), may play an important role in these processes, especially when considering their diffuse cortical connections that mainly express 5-HT<sub>2A</sub> receptors (Tagliazucchi et al., 2016; Doss et al., 2022; compare with Weber and Andrade, 2010). In support of this, it has been recently reported that LSD modulates activity in thalamic nuclei projecting to the prefrontal cortex, thus likely contributing to alteration of consciousness functions (Inserra et al., 2021b). In addition, Timmermann et al. (2023) reported that psychedelics may favor a “global hyper-connectivity,” also collapsing hierarchical organization and reducing intra-network integrity. By means of fMRI/EEG co-registration, they demonstrated that increased “entropy” correlated with decreased alpha power (compare with Annerud Awrohum, 2021), and also showed that regions with the densest expression of 5-HT<sub>2A</sub> receptors (PET data) were the most affected by the psychedelic compound (Timmermann et al., 2023). In this regard, animal models suggest that the effect of psychedelics (e.g., LSD) may be mediated by brain regions and networks that are strongly involved in the control of anxiety (DMN, prefrontal cortex-amygdala circuits and cortico-striato-thalamo-cortical networks; Inserra et al., 2023). Even if more translational research is required to understand the exact mechanisms involved, several studies have demonstrated the anti-anxiety effects of LSD in animals, as well as also reported in clinical trials (compare with Holze et al., 2023). Also, LSD increases social behavior and decreases social anxiety, likely through a prefrontal cortex-mediated effect on glutamatergic neurons, which is paralleled by an increase in mTOR phosphorylation (De Gregorio et al., 2022).

In this context, when considering conditions such as social anxiety disorder (SAD, also characterized by aberrant functional connectivity of the SN/DMN systems; Felsch and Kuypers, 2022) and the possibility to “drive” the effects of psychedelics with assisted intervention (e.g., psychotherapy; *The Lancet Regional Health - Europe*, 2023), evidence suggests that treatments based on psilocybin-assisted meditation might result in clinical changes modulating connectivity of these networks, thus increasing control over amygdala “reactivity” (Felsch and Kuypers, 2022; compare with Carhart-Harris et al., 2017). In fact, SAD is usually characterized by aberrant patterns of brain activity in the amygdala, also comprising regions such as the temporal cortex,

insula, basal nuclei, prefrontal, and cingulate regions (Felsch and Kuypers, 2022). This can be the consequence of pathophysiological and/or maladaptive mechanisms. Evidence of abnormalities in serotonergic and dopaminergic circuits has also been described (Hjorth et al., 2021; Felsch and Kuypers, 2022). As already reported, a common associated characteristic of DS is the development of anxiety, social phobia, and avoidance behaviors (Menzies et al., 1999; Iverach et al., 2011; Iverach and Rapee, 2014). In summary, the possible positive effects of psychedelics on (social) anxiety reinforce the rationale of their utilization in DS.

## A possible therapeutic rationale for psychedelics in DS

The previous sections described the neuropathological mechanisms of DS, as well as the likely mechanisms for psychedelic drugs to act on brain networks. Considering that (frontal) brain metabolism may be aberrant in PWS, and that the “maladaptive” intervention of networks such as the SCN and the DMN could add further “neural noise” to the system (thus worsening the functionality of “goal-directed” networks and behaviors; compare with Alm, 2014; Jackson et al., 2022; Orpella et al., 2024), we propose that controlled treatment with psychedelics should be investigated to help in disrupting maladaptive neural functions in DS, thus restoring a more “adaptive” plasticity in the neural networks involved. More specifically, this should be done in the attempt to reduce social anxiety interacting with speech-motor networks, both precipitating and maintaining stuttering [always keeping in mind that serotonergic drugs may also modulate the functioning of motor excitability in humans (Thorstensen et al., 2024), as well as speech-motor circuits in DS (see Busan et al., 2009)].

This becomes especially significant when considering that, as described above, (persistent) DS is normally associated with a series of associated features and effects, including negative self-perception, negative perception by others, social phobia, avoidance behaviors, anxiety, and depression (Iverach et al., 2011; Iverach and Rapee, 2014; Sander and Osborne, 2019). Indeed, in agreement with a growing body of data, a considerable prevalence of “social” anxiety is evident among PWS (Kraaimaat et al., 2002; Blumgart et al., 2010; Iverach and Rapee, 2014; Iverach et al., 2017), with the clear possibility that these aspects may also act in significantly worsening speech-motor performance and fluency (compare with Alm, 2014; Jackson et al., 2021, 2022; Orpella et al., 2024). A variety of interconnected elements, including the fear of being negatively evaluated (i.e., negative social cognition) and attentional biases (e.g., elevated “self-focused” attention), as well as “anticipatory” and/or “post-event” processing, may have an impact on the development and maintenance of dysfluencies and social anxiety in PWS (see Alm, 2014; Iverach et al., 2017). As mentioned above, stuttering anticipation may be strongly related to overactivation of the right prefrontal cortex (Jackson et al., 2022), thus likely deriving from (or influencing) neural interactions among the DMN, SCN, SN, and TPNs. In fact, excessive involvement of the DMN has been reported to have a role in conditions of psychological ill-health, such as depression and social anxiety (Hamilton et al., 2011). For example, in individuals with major depressive disorder, this



may represent the neural substrate for experiencing higher levels of maladaptive rumination (Hamilton et al., 2011). Accordingly, studies of psilocybin have shown promising results in these disorders (Lowe et al., 2022), and reduced overactivation of the DMN could be a key factor (Smigielski et al., 2019; Aday et al., 2020; Gattuso et al., 2023). In this context, since it has also been demonstrated that, for example, LSD can improve social behavior (De Gregorio et al., 2021) and stress-induced anxiety (De Gregorio et al., 2022), psychedelics could act on DS by improving social anxiety and generalized anxiety. Indeed, a repeated LSD regimen increases social behavior in mice by activating glutamatergic neurons in the prefrontal cortex, potentiating synaptic responses of 5-HT<sub>2A</sub> and AMPA receptors (De Gregorio et al., 2021), as well as reversing the 5-HT firing deficiency induced by stress, thus alleviating anxiety (De Gregorio et al., 2022).

When considering emotion encoding and processing, the amygdala is a key anatomical region in the limbic system (Šimić et al., 2021) and it has been demonstrated that classic psychedelics can modulate its responsiveness (Kraehenmann et al., 2015; Carhart-Harris et al., 2017; Mueller et al., 2017; Roseman et al., 2018). In general, increased amygdala activation may be a neurophysiologic response that could be considered as a “neural marker” of pathological conditions such as PTSD (Francati et al., 2007). Despite the limited evidence regarding the involvement of the limbic system in stuttering, recent studies have sustained the role of amygdala activation in persistent DS (Yang et al., 2017; Toyomura et al., 2018). For example, amygdala was found to significantly correlate with occurrence of disfluencies in PWS (Toyomura et al., 2018). Interestingly, psychedelics have been demonstrated to induce dynamic structural/functional plastic modulations in “fear-extinction” neural circuits, thus tempering/modulating the amygdala’s hyper-reactivity to threat-related stimuli (Glavonic et al., 2022). Similarly, changes in amygdala and prefrontal functional connectivity have been reported during emotional processing after administration of psilocybin for treatment-resistant depression (Mertens et al., 2020). Psychedelic-induced plasticity may also need the recruitment of other structures, such as astrocytes, to promote their effects (Martin and Nichols, 2016). Interestingly, as mentioned above, astrocytes may also play a role in the impaired neural metabolism related to DS (Maguire et al., 2021; Turk et al., 2021). In this context, Maguire et al. (2021) showed that the positive effects of risperidone on stuttering may be the consequence of an increase in brain metabolism, possibly mediated by astrocytes.

In summary, a range of evidence from the use of psychedelics [in various conditions which may or not share some features with DS -e.g., characteristics of SAD and PTSD; compare, for example, with Etkin and Wager (2007), Francati et al. (2007), Felsch and Kuypers (2022)] supports the theoretical foundations to test the impact of this class of drugs on DS. In addition, Jackson et al. (2024) conducted a qualitative analysis to explore potential benefits and negative effects of psychedelics on stuttering, starting from anecdotal evidence of PWS using psychedelics for recreational purposes. About 75% of subjects reported some overall positive effects. More specifically, 60% of participants indicated positive behavioral changes such as reduced stuttering and increased control of speech; 40% reported positive emotional benefits, 15% reported some positive cognitive changes, and 7% indicated some additional positive social effects. On the other hand, about 10% of participants

reported some negative behavioral effects, such as increased stuttering or reduced speech control. Moreover, there is a very recent case-report of resolution of stuttering during treatment with ketamine (Bolton et al., 2023; ketamine is considered a psychedelic drug, even if not part of the classic psychedelics group; compare with Aleksandrova and Phillips, 2021). In this case, a 60-year-old woman who had been a lifelong stutterer was prescribed ketamine for an unrelated condition (i.e., depression), and experienced an almost immediate resolution of stuttering. All considered, and also bearing in mind their fast anxiolytic component (Dos Santos et al., 2016), this evidence might call for the possible evaluation of the effects of psychedelics in the context of persistent DS in adulthood. For example, since trauma-informed therapies are useful for some PWS, incorporating psychedelic treatment may be worth exploring in stuttering.

## Conclusion

DS still represents an unsolved and often underestimated health challenge in terms of its impact on overall quality of life (Craig et al., 2009). Thus, research oriented to investigate new possible therapeutic agents is needed, particularly given the often limited or unsustainable effects of current behavioral interventions (Nye et al., 2013). Paradoxically, some of the previously tested pharmacological substances known to lessen stuttering in some persons have also been found able to “induce” it in others (i.e., drug-induced stuttering; Brady, 1998; Alm, 2004; Ekhardt et al., 2021), likely due to its complex and not yet fully defined etiology, as well as to possible high inter-patient variability (Brady, 1991; Alm, 2004). In this regard, randomized clinical trials (RCTs) focusing on drug interventions for persistent stuttering have shown mixed results (Maguire et al., 2020). In summary, the complexity of stuttering (e.g., with potential sub-types and varying responses to treatments) makes it challenging to draw definitive conclusions.

As a consequence, DS might benefit from further exploring the potential of clinical investigations of psychedelics in (adult) PWS. To date (to the best of our knowledge), there are no registered and/or completed RCTs investigating the possible efficacy of this class of drugs in DS (apart from anecdotal evidence; Bolton et al., 2023; Jackson et al., 2024). In this regard, prospective, randomized, blinded, and controlled trials will be required to understand the efficacy and safety of psychedelic therapies for the treatment of DS. More specifically, the design of such trials will need to answer questions such as: (i) which compounds should be considered, thus defining optimal doses, possible effects, and duration of therapy; (ii) whether repetitive micro-dosing or bolus-dosing will lead to better outcomes; (iii) the main inclusion/exclusion criteria for treatment, as well as the outcomes and measures that should be considered to demonstrate efficacy; (iv) if association with guided psychotherapy (or speech therapy) will lead to better outcomes; (v) if psychedelics could be an option for any person who stutters. From a methodological point of view, we can anticipate that RCTs evaluating psychedelics in DS should consider the effects on stuttering severity and social anxiety as primary outcomes, perhaps also considering secondary outcomes such as communication attitudes and/or evaluation of neurophysiological underpinnings (e.g., pre- vs. post-treatment functional connectivity

of the brain, measured by fMRI and/or EEG). In this context, we can hypothesize that psychedelic treatment would be able to support higher “energy” resources to impaired speech-motor circuits in DS (thus, improving the stuttering “trait”), likely resulting in more “focused” neural activity during “goal-directed” behavior (e.g., propositional speech). This should also allow for lower levels of social anxiety and improved speech fluency in PWS (thus, improving the stuttering “state”).

The evidence suggests that, if correctly administered, psychedelics may be useful and safe (also considering secondary effects -e.g., hallucinogenic ones-; [Dos Santos et al., 2018](#); [Schlag et al., 2022](#); compare with [Holze et al., 2022a,b](#)), helping to treat and better understand brain (network) anomalies related to (psychiatric) disorders. When considering the risk for negative effects, settings and support during sessions are essential ([Aday et al., 2020](#)). It has been reported that almost a third of participants experience acute anxiety at some point during sessions with high dose, while, on the other hand, it has also been shown that no long-term negative effects occurred in studies involving more than 2,000 persons (see [Ross et al., 2016](#); [Aday et al., 2020](#)).

In this context, the landscape surrounding psychedelic research and therapy is rapidly evolving, with increasing interest and recognition of their therapeutic potential. However, navigating the legal and ethical complexities remains a significant challenge for researchers, clinicians, and policymakers alike. In 2024, the decision to administer psychedelics nationally or within a specific state in the United States is largely determined by regulatory bodies such as the Food and Drug Administration (FDA) at the federal level as well as state-level legislative bodies. The FDA oversees the approval process for clinical trials involving psychedelics and other drugs, ensuring that they meet standards for safety and efficacy. However, individual states may also have their own regulations governing the use of psychedelics in research or therapeutic settings. For example, Oregon has legalized the sales of psychedelics, while in Colorado the use of psilocybin is allowed only in psychiatric settings. Similarly, in June 2023, Australia legalized the use of these drugs by psychiatrists (see [Haridy, 2023](#)). Outside the US, regulations vary significantly from country to country.<sup>1</sup> In some nations, psychedelics may be strictly prohibited, while in others they may be legal for certain therapeutic purposes or subject to medical research under specific regulations. For example, Canada has permitted the use of psilocybin in a context of special access programs, where psychiatrists or physicians can make a request in case of treatment-resistant depression, PTSD, or end-of-life anxiety.

In conclusion, we suggest that, starting from observational data collected from PWS who self-medicate stuttering with psychedelics ([Bolton et al., 2023](#); [Jackson et al., 2024](#)), their effects could be also investigated more in depth in the context of an underestimated speech-motor fluency disorder that strongly impairs quality of life of people with DS, thus contributing to boost and improve outcomes of currently available interventions (e.g., speech therapy). Currently, our team is actively trying to progress toward the obtaining of funding for conducting sponsored RCTs, drawing upon the scientific rationale outlined herein. This initiative represents a concerted effort to translate theoretical hypotheses into practical/empirical research.

<sup>1</sup> <https://psychedelicalpha.com/data/worldwide-psychedelic-laws>

## Data availability statement

The original contributions presented in this study are included in this article/supplementary material, further inquiries can be directed to the corresponding author.

## Author contributions

GP: Conceptualization, Formal analysis, Investigation, Project administration, Supervision, Writing – original draft, Writing – review & editing. PB: Formal analysis, Funding acquisition, Investigation, Resources, Supervision, Visualization, Writing – review & editing. EJ: Writing – review & editing. PA: Writing – review & editing. DD: Writing – review & editing. GM: Resources, Writing – review & editing. GuG: Supervision, Writing – review & editing. GaG: Validation, Writing – review & editing. DE: Writing – review & editing. RC-H: Supervision, Validation, Writing – review & editing.

## Funding

The authors declare that financial support was received for the research, authorship, and/or publication of this article. PB was supported by the Italian Ministry of Health (project code: GR-2018-12366027).

## Acknowledgments

PB was grateful to the Italian Ministry of Health (project code: GR-2018-12366027) for financial support. GP expressed sincere gratitude to Mrs Yasmin Azaadeh (University of Birmingham) for her insights and enriching scientific discussions. Authors thank Dr. Patrick Moore for revision of linguistics.

## Conflict of interest

GM reported a conflict of receiving research support and scientific consulting fees from Noema. GaG received a research grant from Diamond Therapeutics, Toronto (ON), Canada. DD was a consultant for Diamond Therapeutics, Toronto (ON), Canada. GaG and DD were inventors of a patent on the use of psychedelics. GuG was Chief Medical Officer at Compass pathways, holds shares and options in Compass pathways and has served as consultant, advisor or CME speaker in the last 3 years for Beckley Psytech, Boehringer Ingelheim, Clerkenwell Health, Compass pathways, Evapharma, Janssen, Lundbeck, Medscape, Novartis, Ocean Neuroscience, P1Vital, Sage, Servier, and Takeda. DE was a paid advisor for Aya Biosciences, Clerkenwell Health, and Mindstate Design Lab. RC-H reported receiving consulting fees from COMPASS Pathways, Entheon Biomedical, Mydecine, Synthesis Institute, Tryp Therapeutics, and Usona Institute.

The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

## Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated

organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

## References

- Aday, J., Mitzkovitz, C., Bloesch, E., Davoli, C., and Davis, A. (2020). Long-term effects of psychedelic drugs: a systematic review. *Neurosci. Biobehav. Rev.* 113, 179–189. doi: 10.1016/j.neubiorev.2020.03.017
- Aghajanian, G., and Marek, G. (1997). Serotonin induces excitatory postsynaptic potentials in apical dendrites of neocortical pyramidal cells. *Neuropharmacology* 36, 589–599. doi: 10.1016/S0028-3908(97)00051-8
- Aleksandrova, L., and Phillips, A. (2021). Neuroplasticity as a convergent mechanism of ketamine and classical psychedelics. *Trends Pharmacol. Sci.* 42, 929–942. doi: 10.1016/j.tips.2021.08.003
- Alm, P. (2004). Stuttering and the basal ganglia circuits: a critical review of possible relations. *J. Commun. Disord.* 37, 325–369. doi: 10.1016/j.jcomdis.2004.03.001
- Alm, P. (2014). Stuttering in relation to anxiety, temperament, and personality: a review and analysis with focus on causality. *J. Fluency Disord.* 40, 5–21. doi: 10.1016/j.jfludis.2014.01.004
- Alm, P. (2020). Streptococcal Infection as a major historical cause of stuttering: data, mechanisms, and current importance. *Front. Hum. Neurosci.* 14:569519. doi: 10.3389/fnhum.2020.569519
- Alm, P. (2021a). Stuttering: a disorder of energy supply to neurons? *Front. Hum. Neurosci.* 15:662204. doi: 10.3389/fnhum.2021.662204
- Alm, P. (2021b). The dopamine system and automatization of movement sequences: a review with relevance for speech and stuttering. *Front. Hum. Neurosci.* 15:661880. doi: 10.3389/fnhum.2021.661880
- American Psychiatric Association (2013). *Diagnostic and Statistical Manual of Mental Disorders*, 5th Edn. Washington, CD: APA. doi: 10.1176/appi.books.9780890425596
- Amodio, D., and Frith, C. (2006). Meeting of minds: the medial frontal cortex and social cognition. *Nat. Rev. Neurosci.* 7, 268–277. doi: 10.1038/nrn1884
- Andrews-Hanna, J., Smallwood, J., and Spreng, R. (2014). The default network and self-generated thought: component processes, dynamic control, and clinical relevance. *Ann. N. Y. Acad. Sci.* 1316, 29–52. doi: 10.1111/nyas.12360
- Annerud Awrohum, S. (2021). *Psychedellic Oscillations: a Systematic Review of the Electrophysiological Correlates of Classic Psychedelics*. Skövde: University of Skövde.
- Arenas, R. (2017). Conceptualizing and investigating the contextual variability of stuttering: the speech and monitoring interaction (SAMI) framework. *Speech Lang. Hear.* 20, 15–28. doi: 10.1080/2050571X.2016.1221877
- Barnes, T., Wozniak, D., Gutierrez, J., Han, T., Drayna, D., and Holy, T. E. A. (2016). mutation associated with stuttering alters mouse pup ultrasonic vocalizations. *Curr. Biol.* 26, 1009–1018. doi: 10.1016/j.cub.2016.02.068
- Belyk, M., Kraft, S., and Brown, S. (2015). Stuttering as a trait or state - an ALE meta-analysis of neuroimaging studies. *Eur. J. Neurosci.* 41, 275–284. doi: 10.1111/ejn.12765
- Belyk, M., Kraft, S., and Brown, S. (2017). Stuttering as a trait or a state revisited: motor system involvement in persistent developmental stuttering. *Eur. J. Neurosci.* 45, 622–624. doi: 10.1111/ejn.13512
- Benito-Aragón, C., Gonzalez-Sarmiento, R., Liddell, T., Diez, I., d'Oleire Uquillas, F., Ortiz-Terán, L., et al. (2020). Neurofilament-lysosomal genetic intersections in the cortical network of stuttering. *Prog. Neurobiol.* 184:101718. doi: 10.1016/j.pneurobio.2019.101718
- Bloodstein, O. (1975). "Stuttering as tension and fragmentation," in *Stuttering: a Second Symposium*, ed. J. Eisensohn (New York, NY: Harper & Row).
- Bloodstein, O., and Ratner, N. (2008). *A Handbook of Stuttering*, 6th Edn. Clifton Park, NY: Delmar.
- Bloodstein, O., Bernstein Ratner, N., and Brundage, S. B. (2021). *A Handbook on Stuttering*, 7th Edn. San Diego, CA: Plural Publishing Inc.
- Blumenfeld, H. (2016). "Chapter 1 - neuroanatomical basis of consciousness," in *The Neurology of Consciousness*, 2nd Edn, eds S. Laureys, O. Gosseries, and G. Tononi (Cambridge, MA: Academic Press).
- Blumgart, E., Tran, Y., and Craig, A. (2010). Social anxiety disorder in adults who stutter. *Depress Anxiety* 27, 687–692. doi: 10.1002/da.20657
- Bogenschutz, M., Ross, S., Bhatt, S., Baron, T., Forchimes, A., Laska, E., et al. (2022). Percentage of heavy drinking days following psilocybin-assisted psychotherapy vs placebo in the treatment of adult patients with alcohol use disorder: a randomized clinical trial. *JAMA Psychiatry* 79, 953–962. doi: 10.1001/jamapsychiatry.2022.2096
- Bolton, D., Hailu, T., and Porucznik, C. (2023). Resolution of stuttering during ketamine treatment: a case report. *J. Med. Case Rep.* 17:447. doi: 10.1186/s13256-023-04158-8
- Brady, J. (1991). The pharmacology of stuttering: a critical review. *Am. J. Psychiatry* 148, 1309–1316. doi: 10.1176/ajp.148.10.1309
- Brady, J. (1998). Drug-induced stuttering: a review of the literature. *J. Clin. Psychopharmacol.* 18, 50–54. doi: 10.1097/00004714-199802000-00008
- Brocklehurst, P., Lickley, R., and Corley, M. (2013). Revisiting bloodstein's anticipatory struggle hypothesis from a psycholinguistic perspective: a variable release threshold hypothesis of stuttering. *J. Commun. Disord.* 46, 217–237. doi: 10.1016/j.jcomdis.2013.04.002
- Budde, K., Barron, D., and Fox, P. (2014). Stuttering, induced fluency, and natural fluency: a hierarchical series of activation likelihood estimation meta-analyses. *Brain Lang.* 139, 99–107. doi: 10.1016/j.bandl.2014.10.002
- Busan, P. (2020). Developmental stuttering and the role of the supplementary motor cortex. *J. Fluency Disord.* 64:105763. doi: 10.1016/j.jfludis.2020.10.5763
- Busan, P., Battaglini, P., Borelli, M., Evaristo, P., Monti, F., and Pelamatti, G. (2009). Investigating the efficacy of paroxetine in developmental stuttering. *Clin. Neuropharmacol.* 32, 183–188. doi: 10.1097/WNF.0b013e31819817eb
- Busan, P., Battaglini, P., and Sommer, M. (2017). Transcranial magnetic stimulation in developmental stuttering: relations with previous neurophysiological research and future perspectives. *Clin. Neurophysiol.* 128, 952–964. doi: 10.1016/j.clinph.2017.03.039
- Busan, P., D'Ausilio, A., Borelli, M., Monti, F., Pelamatti, G., Pizzolato, G., et al. (2013). Motor excitability evaluation in developmental stuttering: a transcranial magnetic stimulation study. *Cortex* 49, 781–792. doi: 10.1016/j.cortex.2011.12.002
- Busan, P., Del Ben, G., Russo, L., Bernardini, S., Ntarelli, G., Arcara, G., et al. (2019). Stuttering as a matter of delay in neural activation: a combined TMS/EEG study. *Clin. Neurophysiol.* 130, 61–76. doi: 10.1016/j.clinph.2018.10.005
- Busan, P., Del Ben, G., Tantone, A., Halaj, L., Bernardini, S., Ntarelli, G., et al. (2020). Effect of muscular activation on surrounding motor networks in developmental stuttering: a TMS study. *Brain Lang.* 205:104774. doi: 10.1016/j.bandl.2020.104774
- Busan, P., Moret, B., Formaggio, E., Riavisi, L., Pisciotto, C., Masina, F., et al. (2023). High definition-transcranial random noise stimulation to improve speech fluency in persistent developmental stuttering: a case study. *Clin. Neurophysiol.* 152, 71–74. doi: 10.1016/j.clinph.2023.06.001
- Busan, P., Moret, B., Masina, F., Del Ben, G., and Campana, G. (2021). Speech fluency improvement in developmental stuttering using non-invasive brain stimulation: insights from available evidence. *Front. Hum. Neurosci.* 15:662016. doi: 10.3389/fnhum.2021.662016
- Cai, H., Dong, J., Mei, L., Feng, G., Li, L., Wang, G., et al. (2024). Functional and structural abnormalities of the speech disorders: a multimodal activation likelihood estimation meta-analysis. *Cereb. Cortex* 34:bhae075. doi: 10.1093/cercor/bhae075
- Calder, A., and Hasler, G. (2023). Towards an understanding of psychedelic-induced neuroplasticity. *Neuropsychopharmacology* 48, 104–112. doi: 10.1038/s41386-022-01389-z
- Carhart-Harris, R., Erritzoe, D., Williams, T., Stone, J., Reed, L., Colasanti, A., et al. (2012). Neural correlates of the psychedelic state as determined by fMRI studies with psilocybin. *Proc. Natl. Acad. Sci. U S A.* 109, 2138–2143. doi: 10.1073/pnas.1119598109
- Carhart-Harris, R., and Friston, K. J. (2019). Rebus and the anarchic brain: toward a unified model of the brain action of psychedelics. *Pharmacol. Rev.* 71, 316–344. doi: 10.1124/pr.118.017160
- Carhart-Harris, R., Giribaldi, B., Watts, R., Baker-Jones, M., Murphy-Beiner, A., Murphy, R., et al. (2021). Trial of psilocybin versus escitalopram for depression. *N. Engl. J. Med.* 384, 1402–1411. doi: 10.1056/NEJMoa2032994
- Carhart-Harris, R., Leech, R., Erritzoe, D., Williams, T., Stone, J., Evans, J., et al. (2013). Functional connectivity measures after psilocybin inform a novel hypothesis of early psychosis. *Schizophr. Bull.* 39, 1343–1351. doi: 10.1093/schbul/sbs117
- Carhart-Harris, R., Leech, R., Hellyer, P., Shanahan, M., Feilding, A., Tagliazucchi, E., et al. (2014). The entropic brain: a theory of conscious states informed by neuroimaging research with psychedelic drugs. *Front. Hum. Neurosci.* 8:20. doi: 10.3389/fnhum.2014.00020



- Carhart-Harris, R., Roseman, L., Bolstridge, M., Demetriou, L., Pannekoek, J., and Wall, M. (2017). Psilocybin for treatment-resistant depression: fMRI-measured brain mechanisms. *Sci. Rep.* 7:13187. doi: 10.1038/s41598-017-13282-7
- Chang, S., Angstadt, M., Chow, H., Etchell, A., Garnett, E., Choo, A., et al. (2018). Anomalous network architecture of the resting brain in children who stutter. *J. Fluency Disord.* 55, 46–67. doi: 10.1016/j.jfludis.2017.01.002
- Chang, S., Garnett, E., Etchell, A., and Chow, H. (2019). Functional and neuroanatomical bases of developmental stuttering: current insights. *Neuroscientist* 25, 566–582. doi: 10.1177/1073858418803594
- Chang, S., and Guenther, F. (2020). Involvement of the cortico-basal ganglia-thalamo-cortical loop in developmental stuttering. *Front. Psychol.* 10:3088. doi: 10.3389/fpsyg.2019.03088
- Chard, I., Van Zalk, N., and Picinali, L. (2023). Virtual reality exposure therapy for reducing social anxiety in stuttering: a randomized controlled pilot trial. *Digit. Health* 5:1061323. doi: 10.3389/fdgth.2023.1061323
- Chesters, J., Möttönen, R., and Watkins, K. (2018). Transcranial direct current stimulation over left inferior frontal cortex improves speech fluency in adults who stutter. *Brain* 141, 1161–1171. doi: 10.1093/brain/awy011
- Chow, H., Garnett, E., Koenraads, S., and Chang, S. (2023). Brain developmental trajectories associated with childhood stuttering persistence and recovery. *Dev. Cogn. Neurosci.* 60:101224. doi: 10.1016/j.dcn.2023.101224
- Chow, H., Garnett, E., Li, H., Etchell, A., Sepulcre, J., Drayna, D., et al. (2020). Linking lysosomal enzyme targeting genes and energy metabolism with altered gray matter volume in children with persistent stuttering. *Neurobiol. Lang.* 1, 365–380. doi: 10.1162/nol\_a\_00017
- Civier, O., Bullock, D., Max, L., and Guenther, F. (2013). Computational modeling of stuttering caused by impairments in a basal ganglia thalamo-cortical circuit involved in syllable selection and initiation. *Brain Lang.* 126, 263–278. doi: 10.1016/j.bandl.2013.05.016
- Connally, E., Ward, D., Pliatsikas, C., Finnegan, S., Jenkinson, M., Boyles, R., et al. (2018). Separation of trait and state in stuttering. *Hum. Brain Mapp.* 39, 3109–3126. doi: 10.1002/hbm.24063
- Constantino, C., Leslie, P., Quesal, R., and Yaruss, J. S. A. (2016). Preliminary investigation of daily variability of stuttering in adults. *J. Commun. Disord.* 60, 39–50. doi: 10.1016/j.jcomdis.2016.02.001
- Couture, E., Walden, T., Arnold, H., Graham, C., Hartfield, K., and Karrass, J. (2006). “A communication-emotional model of stuttering,” in *Current Issues in Stuttering Research and Practice*, 1st Edn, eds N. Bernstein Ratner and J. A. Tetzowski (London: Psychology Press).
- Corbetta, M., and Shulman, G. (2002). Control of goal-directed and stimulus-driven attention in the brain. *Nat. Rev. Neurosci.* 3, 201–215. doi: 10.1038/nrn755
- Craig, A., Blumgart, E., and Tran, Y. (2009). The impact of stuttering on the quality of life in adults who stutter. *J. Fluency Disord.* 34, 61–71. doi: 10.1016/j.jfludis.2009.05.002
- Craig-McQuaide, A., Akram, H., Zrinzo, L., and Tripoliti, E. (2014). A review of brain circuitries involved in stuttering. *Front. Hum. Neurosci.* 8:884. doi: 10.3389/fnhum.2014.00884
- Davoudian, P., Shao, L., and Kwan, A. (2023). Shared and distinct brain regions targeted for immediate early gene expression by ketamine and psilocybin. *ACS Chem. Neurosci.* 14, 468–480. doi: 10.1021/acscchemneuro.2c00637
- Daws, R., Timmermann, C., Giribaldi, B., Sexton, J., Wall, M., Erritzoe, D., et al. (2022). Increased global integration in the brain after psilocybin therapy for depression. *Nat. Med.* 28, 844–851. doi: 10.1038/s41591-022-01744-z
- De Gregorio, D., Insera, A., Enns, J., Markopoulos, A., Pileggi, M., El Rahimy, Y., et al. (2022). Repeated lysergic acid diethylamide (LSD) reverses stress-induced anxiety-like behavior, cortical synaptogenesis deficits and serotonergic neurotransmission decline. *Neuropsychopharmacology* 47, 1188–1198. doi: 10.1038/s41386-022-01301-9
- De Gregorio, D., Popic, J., Enns, J., Insera, A., Skalecka, A., Markopoulos, A., et al. (2021). Lysergic acid diethylamide (LSD) promotes social behavior through mTORC1 in the excitatory neurotransmission. *Proc. Natl. Acad. Sci. U S A.* 118:e2020705118. doi: 10.1073/pnas.2020705118
- Delpêche, S., Millard, S., and Kelman, E. (2022). The role of temperament in stuttering frequency and impact in children under 7. *J. Commun. Disord.* 97:106201. doi: 10.1016/j.jcomdis.2022.106201
- Desai, J., Huo, Y., Wang, Z., Bansal, R., Williams, S., Lythgoe, D., et al. (2017). Reduced perfusion in Broca's area in developmental stuttering. *Hum. Brain Mapp.* 38, 1865–1874. doi: 10.1002/hbm.23487
- Dolder, P., Schmid, Y., Steuer, A., Kraemer, T., Rentsch, K., Hammann, F., et al. (2017). Pharmacokinetics and pharmacodynamics of lysergic acid diethylamide in healthy subjects. *Clin. Pharmacokinet* 56, 1219–1230. doi: 10.1007/s40262-017-0513-9
- Dos Santos, R., Bousso, J., Alcazar-Corcoles, M., and Hallak, J. (2018). Efficacy, tolerability, and safety of serotonergic psychedelics for the management of mood, anxiety, and substance-use disorders: a systematic review of systematic reviews. *Expert Rev. Clin. Pharmacol.* 11, 889–902. doi: 10.1080/17512433.2018.1511424
- Dos Santos, R., Osório, F., Crippa, J., Riba, J., Zuardi, A., and Hallak, J. (2016). Antidepressive, anxiolytic, and antiaddictive effects of ayahuasca, psilocybin and lysergic acid diethylamide (LSD): a systematic review of clinical trials published in the last 25 years. *Ther. Adv. Psychopharmacol.* 6, 193–213. doi: 10.1177/2045125316638008
- Doss, M., Madden, M., Gaddis, A., Nebel, M., Griffiths, R., Mathur, B., et al. (2022). Models of psychedelic drug action: modulation of cortical-subcortical circuits. *Brain* 145, 441–456. doi: 10.1093/brain/awab406
- Eichorn, N., Marton, K., Schwartz, R., Melara, R., and Pirutinsky, S. (2016). Does working memory enhance or interfere with speech fluency in adults who do and do not stutter? evidence from a dual-task paradigm. *J. Speech Lang. Hear. Res.* 59, 415–429. doi: 10.1044/2015\_JSLHR-S-15-0249
- Eichorn, N., Pirutinsky, S., and Marton, K. (2019). Effects of different attention tasks on concurrent speech in adults who stutter and fluent controls. *J. Fluency Disord.* 61:105714. doi: 10.1016/j.jfludis.2019.105714
- Eisenson, J., and Horowitz, E. (1945). The influence of propositionality on stuttering. *J. Speech Disord.* 10, 193–197. doi: 10.1044/jshd.1003.193
- Ekhart, C., van Hunsel, F., van Harten, P., van Baarsen, J., Yingying, T., and Bast, B. (2021). Drug-induced stuttering: occurrence and possible pathways. *Front. Psychiatry* 12:692568. doi: 10.3389/fpsyg.2021.692568
- Emge, G., and Pellowski, M. (2019). Incorporating a mindfulness meditation exercise into a stuttering treatment program. *Commun. Disord. Quart.* 40, 125–128. doi: 10.1177/1525740118783516
- Etchell, A., Civier, O., Ballard, K., and Sowman, P. F. A. (2018). Systematic literature review of neuroimaging research on DS between 1995 and 2016. *J. Fluency Disord.* 55, 6–45. doi: 10.1016/j.jfludis.2017.03.007
- Etchell, A., Johnson, B., and Sowman, P. (2014). Behavioral and multimodal neuroimaging evidence for a deficit in brain timing networks in stuttering: a hypothesis and theory. *Front. Hum. Neurosci.* 8:467. doi: 10.3389/fnhum.2014.00467
- Etchell, A., Johnson, B., and Sowman, P. (2015). Beta oscillations, timing, and stuttering. *Front. Hum. Neurosci.* 8:1036. doi: 10.3389/fnhum.2014.01036
- Etkin, A., and Wager, T. (2007). Functional neuroimaging of anxiety: a meta-analysis of emotional processing in PTSD, social anxiety disorder, and specific phobia. *Am. J. Psychiatry* 164, 1476–1488. doi: 10.1176/appi.ajp.2007.07030504
- Felsch, C., and Kuypers, K. (2022). Don't be afraid, try to meditate- potential effects on neural activity and connectivity of psilocybin-assisted mindfulness-based intervention for social anxiety disorder: a systematic review. *Neurosci. Biobehav. Rev.* 139:104724. doi: 10.1016/j.neubiorev.2022.104724
- Fernandes Coutinho, J., Veiga Fernandes, S., Soares, J., Maia, L., Gonçalves, O., and Sampaio, A. (2016). Default mode network dissociation in depressive and anxiety states. *Brain Imaging Behav.* 10, 147–157. doi: 10.1007/s11682-015-9375-7
- Finizio, T., Pool, K., Freeman, F., Devous, M., and Watson, B. (1991). “Cortical dysfunction in developmental stutterers,” in *Speech Motor Control and Stuttering, Proceedings of the 2nd International Conference, Held in Nijmegen, the Netherlands, June 13–16, (Amsterdam: Excerpta Medica, Inc.)*.
- Francati, V., Vermetten, E., and Bremner, J. (2007). Functional neuroimaging studies in posttraumatic stress disorder: review of current methods and findings. *Depress Anxiety* 24, 202–218. doi: 10.1002/da.20208
- Frigerio-Domingues, C., and Drayna, D. (2017). Genetic contributions to stuttering: the current evidence. *Mol. Genet. Genom. Med.* 5, 95–102. doi: 10.1002/mgg3.276
- Fuentes, J., Fonseca, F., Elices, M., Farré, M., and Torrens, M. (2020). Therapeutic use of LSD in psychiatry: a systematic review of randomized-controlled clinical trials. *Front. Psychiatry* 10:943. doi: 10.3389/fpsyg.2019.00943
- García-Barrera, M., and Davidow, J. (2015). Anticipation in stuttering: a theoretical model of the nature of stutter prediction. *J. Fluency Disord.* 44, 1–15. doi: 10.1016/j.jfludis.2015.03.002
- Garnett, E., Chow, H., Choo, A., and Chang, S. (2019). Stuttering severity modulates effects of non-invasive brain stimulation in adults who stutter. *Front. Hum. Neurosci.* 13:411. doi: 10.3389/fnhum.2019.00411
- Garnett, E., Chow, H., Limb, S., Liu, Y., and Chang, S. (2022). Neural activity during solo and choral reading: a functional magnetic resonance imaging study of overt continuous speech production in adults who stutter. *Front. Hum. Neurosci.* 16:894676. doi: 10.3389/fnhum.2022.894676
- Gasser, P., Holstein, D., Michel, Y., Doblin, R., Yazar-Klosinski, B., Passie, T., et al. (2014). Safety and efficacy of lysergic acid diethylamide-assisted psychotherapy for anxiety associated with life-threatening diseases. *J. Nerv. Ment. Dis.* 202, 513–520. doi: 10.1097/NMD.0000000000000113
- Gasser, P., Kirchner, K., and Passie, T. L. S. D. - (2015). Assisted psychotherapy for anxiety associated with a life-threatening disease: a qualitative study of acute and sustained subjective effects. *J. Psychopharmacol.* 29, 57–68. doi: 10.1177/0269881114555249
- Gastaldon, S., Busan, P., Arcara, G., and Peressotti, F. (2023). Inefficient speech-motor control affects predictive speech comprehension: atypical electrophysiological correlates in stuttering. *Cereb. Cortex* 33, 6834–6851. doi: 10.1093/cercor/bhad004



- Gattuso, J., Perkins, D., Ruffell, S., Lawrence, A., Hoyer, D., Jacobson, L., et al. (2023). Default mode network modulation by psychedelics: a systematic review. *Int. J. Neuropsychopharmacol.* 26, 155–188. doi: 10.1093/ijnp/pyac074
- Ghaderi, A., Andevari, M., and Sowman, P. (2018). Evidence for a resting state network abnormality in adults who stutter. *Front. Integr. Neurosci.* 12:16. doi: 10.3389/fnint.2018.00016
- Girn, M., Roseman, L., Bernhardt, B., Smallwood, J., Carhart-Harris, R., and Nathan Spreng, R. (2022). Serotonergic psychedelic drugs LSD and psilocybin reduce the hierarchical differentiation of unimodal and transmodal cortex. *NeuroImage* 256:119220. doi: 10.1016/j.neuroimage.2022.119220
- Glavonic, E., Mitic, M., and Adzic, M. (2022). Hallucinogenic drugs and their potential for treating fear-related disorders: through the lens of fear extinction. *J. Neurosci. Res.* 100, 947–969. doi: 10.1002/jnr.25017
- Gobbi, G., Inserra, A., Greenway, K., Lifshitz, M., and Kirmayer, L. (2022). Psychedelic medicine at a crossroads: advancing an integrative approach to research and practice. *Transcult. Psychiatry* 59, 718–724. doi: 10.1177/13634615221119388
- Good, M., Joel, Z., Benway, T., Routledge, C., Timmermann, C., Erritzoe, D., et al. (2023). Pharmacokinetics of N,N-dimethyltryptamine in humans. *Eur. J. Drug Metab. Pharmacokinet* 48, 311–327. doi: 10.1007/s13318-023-00822-y
- Goodwin, G., Aaronson, S., Alvarez, O., Arden, P., Baker, A., Bennett, J., et al. (2022). Single-dose psilocybin for a treatment-resistant episode of major depression. *N. Engl. J. Med.* 387, 1637–1648. doi: 10.1056/NEJMoa2206443
- Gratton, C., Sun, H., and Petersen, S. (2018). Control networks and hubs. *Psychophysiology* 55, doi: 10.1111/psyp.13032
- Griffiths, R., Richards, W., Johnson, M., McCann, U., and Jesse, R. (2008). Mystical-type experiences occasioned by psilocybin mediate the attribution of personal meaning and spiritual significance 14 months later. *J. Psychopharmacol.* 22, 621–632. doi: 10.1177/0269881108094300
- Gunn, A., Menzies, R., Onslow, M., O'Brian, S., Packman, A., Lowe, R., et al. (2019). Phase I trial of a standalone internet social anxiety treatment for adolescents who stutter: iBroadway. *Int. J. Lang. Commun. Disord.* 54, 927–939. doi: 10.1111/1460-6984.12496
- Hamilton, J., Furman, D., Chang, C., Thomason, M., Dennis, E., and Gotlib, I. (2011). Default-mode and task-positive network activity in major depressive disorder: implications for adaptive and maladaptive rumination. *Biol. Psychiatry* 70, 327–333. doi: 10.1016/j.biopsych.2011.02.003
- Han, T., Root, J., Reyes, L., Hutchinson, E., du Hoffmann, J., Lee, W., et al. (2019). Human GNPTAB stuttering mutations engineered into mice cause vocalization deficits and astrocyte pathology in the corpus callosum. *Proc. Natl. Acad. Sci.* 116, 17515–17524. doi: 10.1073/pnas.1901480116
- Haridy, R. (2023). Australia to prescribe MDMA and psilocybin for PTSD and depression in world first. *Nature* 619, 227–228. doi: 10.1038/d41586-023-02093-8
- Healey E. C., Scott Trautman L., and Susca M. (2004). Clinical applications of a multidimensional approach for the assessment and treatment of stuttering. *Contemp. Issues Commun. Sci. Disorder.* 31, 40–48.
- Herzog, R., Mediano, P., Rosas, F., Lodder, P., Carhart-Harris, R., Sanz Perl, Y., et al. (2023). A whole-brain model of the neural entropy increase elicited by psychedelic drugs. *Sci. Rep.* 13:6244. doi: 10.1038/s41598-023-32649-7
- Hirota, K., and Lambert, D. (2022). Ketamine; history and role in anesthetic pharmacology. *Neuropharmacology* 216:109171. doi: 10.1016/j.neuropharm.2022.109171
- Hjorth, O., Frick, A., Gingnell, M., Hoppe, J., Faria, V., and Hultberg, S. (2021). Expression and co-expression of serotonin and dopamine transporters in social anxiety disorder: a multitracer positron emission tomography study. *Mol. Psychiatry* 26, 3970–3979. doi: 10.1038/s41380-019-0618-7
- Holze, F., Caluori, T., Vizeli, P., and Liechti, M. (2022a). Safety pharmacology of acute LSD administration in healthy subjects. *Psychopharmacology* 239, 1893–1905. doi: 10.1007/s00213-021-05978-6
- Holze, F., Ley, L., Müller, F., Becker, A., Straumann, I., Vizeli, P., et al. (2022b). Direct comparison of the acute effects of lysergic acid diethylamide and psilocybin in a double-blind placebo-controlled study in healthy subjects. *Neuropsychopharmacology* 47, 1180–1187. doi: 10.1038/s41386-022-01297-2
- Holze, F., Gasser, P., Müller, F., Dolder, P., and Liechti, M. (2023). Lysergic acid diethylamide-assisted therapy in patients with anxiety with and without a life-threatening illness: a randomized, double-blind, placebo-controlled phase II study. *Biol. Psychiatry* 93, 215–223. doi: 10.1016/j.biopsych.2022.08.025
- Inserra, A., Campanale, A., Cheishvili, D., Dymov, S., Wong, A., Marcal, N., et al. (2022). Modulation of DNA methylation and protein expression in the prefrontal cortex by repeated administration of D-lysergic acid diethylamide (LSD): Impact on neurotropic, neurotrophic, and neuroplasticity signaling. *Prog. Neuropsychopharmacol. Biol. Psychiatry* 119:110594. doi: 10.1016/j.pnpbp.2022.110594
- Inserra, A., Piot, A., De Gregorio, D., and Gobbi, G. (2023). Lysergic acid diethylamide (LSD) for the treatment of anxiety disorders: Preclinical and clinical evidence. *CNS Drugs* 37, 733–754. doi: 10.1007/s40263-023-01008-5
- Inserra, A., De Gregorio, D., and Gobbi, G. (2021a). Psychedelics in psychiatry: neuroplastic, immunomodulatory, and neurotransmitter mechanisms. *Pharmacol. Rev.* 73, 202–277. doi: 10.1124/pharmrev.120.000056
- Inserra, A., De Gregorio, D., Rezaei, T., Lopez-Canul, M., Comai, S., and Gobbi, G. (2021b). Lysergic acid diethylamide differentially modulates the reticular thalamus, mediodorsal thalamus, and infralimbic prefrontal cortex: an in vivo electrophysiology study in male mice. *J. Psychopharmacol.* 35, 469–482. doi: 10.1177/02698811211991569
- Iverach, L., Menzies, R., O'Brian, S., Packman, A., and Onslow, M. (2011). Anxiety and stuttering: continuing to explore a complex relationship. *Am. J. Speech Lang. Pathol.* 20, 221–232. doi: 10.1044/1058-0360(2011/10-0091)
- Iverach, L., O'Brian, S., Jones, M., Block, S., Lincoln, M., Harrison, E., et al. (2009). Prevalence of anxiety disorders among adults seeking speech therapy for stuttering. *J. Anxiety Disord.* 23, 928–934. doi: 10.1016/j.janxdis.2009.06.003
- Iverach, L., and Rapee, R. (2014). Social anxiety disorder and stuttering: current status and future directions. *J. Fluency Disord.* 40, 69–82. doi: 10.1016/j.jfludis.2013.08.003
- Iverach, L., Rapee, R., Wong, Q., and Lowe, R. (2017). Maintenance of social anxiety in stuttering: a cognitive-behavioral model. *Am. J. Speech Lang. Pathol.* 26, 540–556. doi: 10.1044/2016\_AJSLP-16-0033
- Jackson, E., Draivida, S., Zhang, X., Noah, J., Gracco, V., and Hirsch, J. (2022). Activation in right dorsolateral prefrontal cortex underlies stuttering anticipation. *Neurobiol. Lang.* 3, 469–494. doi: 10.1162/nol\_a\_00073
- Jackson, E., Gerlach, H., Rodgers, N., and Zebrowski, P. (2018). My client knows that he's about to stutter: how can we address stuttering anticipation during therapy with young people who stutter? *Semin. Speech Lang.* 39, 356–370. doi: 10.1055/s-0038-1667164
- Jackson, E., Miller, L., Warner, H., and Yaruss, J. (2021). Adults who stutter do not stutter during private speech. *J. Fluency Disord.* 70:105878. doi: 10.1016/j.jfludis.2021.105878
- Jackson, E., Rodgers, N., and Rodgers, D. (2019). An exploratory factor analysis of action responses to stuttering anticipation. *J. Fluency Disord.* 60, 1–10. doi: 10.1016/j.jfludis.2019.03.001
- Jackson, E., Tiede, M., Beal, D., and Whalen, D. (2016). The impact of social-cognitive stress on speech variability, determinism, and stability in adults who do and do not stutter. *J. Speech Lang. Hear. Res.* 59, 1295–1314. doi: 10.1044/2016\_JSLHR-S-16-0145
- Jackson, E., Yaruss, J., Quesal, R., Terranova, V., and Whalen, D. (2015). Responses of adults who stutter to the anticipation of stuttering. *J. Fluency Disord.* 45, 38–51. doi: 10.1016/j.jfludis.2015.05.002
- Jackson, E. S., Goldway, N., Gerlach-Houck, H., and Gold, N. D. (2024). Stutterers' experiences on classic psychedelics: A preliminary self-report study. *J. Fluency Disord.* Advance online publication. doi: 10.1016/j.jfludis.2024.106062
- Jenson, D., Bowers, A., Hudock, D., and Saltuklaroglu, T. (2020). The application of EEG mu rhythm measures to neurophysiological research in stuttering. *Front. Hum. Neurosci.* 13:458. doi: 10.3389/fnhum.2019.00458
- Joos, K., De Ridder, D., Boey, R., and Vanneste, S. (2014). Functional connectivity changes in adults with developmental stuttering: a preliminary study using quantitative electro-encephalography. *Front. Hum. Neurosci.* 8:783. doi: 10.3389/fnhum.2014.00783
- Junuzovic-Zunic, L., Sinanovic, O., and Majic, B. (2021). Neurogenic stuttering: etiology, symptomatology, and treatment. *Med. Arch.* 75, 456–461. doi: 10.5455/medarh.2021.75.456-461
- Kal, E., van der Kamp, J., and Houdijk, H. (2013). External attentional focus enhances movement automatization: a comprehensive test of the constrained action hypothesis. *Hum. Mov. Sci.* 32, 527–539. doi: 10.1016/j.humov.2013.04.001
- Kang, C., and Drayna, D. A. (2012). role for inherited metabolic deficits in persistent developmental stuttering. *Mol. Genet. Metab.* 107, 276–280. doi: 10.1016/j.ymgme.2012.07.020
- Kang, C., Riazuddin, S., Mundorff, J., Krasnewich, D., Friedman, P., Mullikin, J., et al. (2010). Mutations in the lysosomal enzyme-targeting pathway and persistent stuttering. *N. Engl. J. Med.* 362, 677–685. doi: 10.1056/NEJMoa0902630
- Kincade, J., Abrams, R., Astafiev, S., Shulman, G., and Corbetta, M. (2005). An event-related functional magnetic resonance imaging study of voluntary and stimulus-driven orienting of attention. *J. Neurosci.* 25, 4593–4604. doi: 10.1523/JNEUROSCI.0236-05.2005
- Korzeczek, A., Neef, N., Steinmann, I., Paulus, W., and Sommer, M. (2022). Stuttering severity relates to frontotemporal low-beta synchronization during pre-speech preparation. *Clin. Neurophysiol.* 138, 84–96. doi: 10.1016/j.clinph.2022.03.010
- Kraaimaat, F., Vanryckeghem, M., and Van Dam-Baggen, R. (2002). Stuttering and social anxiety. *J. Fluency Disord.* 27, 319–330. doi: 10.1016/S0094-730X(02)00160-2
- Kraehenmann, R., Preller, K., Scheidegger, M., Pokorny, T., Bosch, O., Seifritz, E., et al. (2015). Psilocybin-induced decrease in amygdala reactivity correlates with enhanced positive mood in healthy volunteers. *Biol. Psychiatry* 78, 572–581. doi: 10.1016/j.biopsych.2014.04.010

- Kraft, S., and Yairi, E. (2012). Genetic bases of stuttering: the state of the art, 2011. *Folia Phoniatr Logop* 64, 34–47. doi: 10.1159/000331073
- Kronfeld-Duenias, V., Amir, O., Ezrati-Vinacour, R., Civier, O., and Ben-Shachar, M. (2016). The frontal aslant tract underlies speech fluency in persistent developmental stuttering. *Brain Struct. Funct.* 221, 365–381. doi: 10.1007/s00429-014-0912-8
- Lewis, C., Preller, K., Kraehenmann, R., Michels, L., Staempfli, P., and Vollenweider, F. (2017). Two dose investigation of the 5-HT-agonist psilocybin on relative and global cerebral blood flow. *Neuroimage* 159, 70–78. doi: 10.1016/j.neuroimage.2017.07.020
- Ling, S., Ceban, F., Lui, L., Lee, Y., and Teopiz, K. (2022). Rodrigues et al. Molecular mechanisms of psilocybin and implications for the treatment of depression. *CNS Drugs* 36, 17–30. doi: 10.1007/s40263-021-00877-y
- Lowe, H., Toyang, N., Steele, B., Grant, J., Ali, A., Gordon, L., et al. (2022). Psychedelics: alternative and potential therapeutic options for treating mood and anxiety disorders. *Molecules* 27:2520. doi: 10.3390/molecules27082520
- Lowe, R., Menzies, R., Onslow, M., Packman, A., and O'Brian, S. (2021). Speech and anxiety management with persistent stuttering: current status and essential research. *J. Speech Lang. Hear. Res.* 64, 59–74. doi: 10.1044/2020\_JSLHR-20-00144
- Ludlow, C., and Loucks, T. (2003). Stuttering: a dynamic motor control disorder. *J. Fluency Disord.* 28, 273–295. doi: 10.1016/j.jfludis.2003.07.001
- Luoma, J., Chwyl, C., Bathje, G., Davis, A., and Lancelotta, R. A. (2020). meta-analysis of placebo-controlled trials of psychedelic-assisted therapy. *J. Psychoactive Drugs* 52, 289–299. doi: 10.1080/02791072.2020.1769878
- Ly, C., Greb, A., Cameron, L., Wong, J., Barragan, E., Wilson, P., et al. (2018). Psychedelics promote structural and functional neural plasticity. *Cell Rep.* 23, 3170–3182. doi: 10.1016/j.celrep.2018.05.022
- Maguire, G., Nguyen, D., Simonson, K., and Kurz, T. (2020). The pharmacologic treatment of stuttering and its neuropharmacologic basis. *Front. Neurosci.* 14:158. doi: 10.3389/fnins.2020.00158
- Maguire, G., Yoo, B., and SheikhBahaei, S. (2021). Investigation of risperidone treatment associated with enhanced brain activity in patients who stutter. *Front. Neurosci.* 15:100. doi: 10.3389/fnins.2021.598949
- Martin, D., and Nichols, C. (2016). Psychedelics recruit multiple cellular types and produce complex transcriptional responses within the brain. *EBioMedicine* 11, 262–277. doi: 10.1016/j.ebiom.2016.08.049
- Matsushashi, K., Itahashi, T., Aoki, R., and Hashimoto, R. (2023). Meta-analysis of structural integrity of white matter and functional connectivity in developmental stuttering. *Brain Res. Bull.* 205:110827. doi: 10.1016/j.brainresbull.2023.110827
- McNevin, N., Shea, C., and Wulf, G. (2003). Increasing the distance of an external focus of attention enhances learning. *Psychol. Res.* 67, 22–29. doi: 10.1007/s00426-002-0093-6
- Menzies, R., Onslow, M., and Packman, A. (1999). Anxiety and stuttering: exploring a complex relationship. *Am. J. Speech Lang. Pathol.* 8, 3–10. doi: 10.1044/1058-0360.0801.03
- Menzies, R., Packman, A., Onslow, M., O'Brian, S., Jones, M., and Helgadóttir, F. (2019). In-clinic and standalone internet cognitive behavior therapy treatment for social anxiety in stuttering: a randomized trial of iGlebe. *J. Speech Lang. Hear. Res.* 62, 1614–1624. doi: 10.1044/2019\_JSLHR-S-18-0340
- Mertens, L., Wall, M., Roseman, L., Demetriou, L., Nutt, D., and Carhart-Harris, R. (2020). Therapeutic mechanisms of psilocybin: changes in amygdala and prefrontal functional connectivity during emotional processing after psilocybin for treatment-resistant depression. *J. Psychopharmacol.* 34, 167–180. doi: 10.1177/0269881119895520
- Moliner, R., Gyrych, M., Brunello, C., Kovaleva, V., Biojone, C., Enkavi, G., et al. (2023). Psychedelics promote plasticity by directly binding to BDNF receptor TrkB. *Nat. Neurosci.* 26, 1032–1041. doi: 10.1038/s41593-023-01316-5
- Montag, C., Bleek, B., Reuter, M., Müller, T., Weber, B., Faber, J., et al. (2019). Ventral striatum and stuttering: robust evidence from a case-control study applying DARTEL. *NeuroImage Clin.* 23:101890. doi: 10.1016/j.nicl.2019.101890
- Moran, J., Macrae, C., Heatherton, T., Wyland, C., and Kelley, W. (2006). Neuroanatomical evidence for distinct cognitive and affective components of self. *J. Cogn. Neurosci.* 18, 1586–1594. doi: 10.1162/jocn.2006.18.9.1586
- Moujaes, F., Preller, K., Ji, J., Murray, J., Berkovitch, L., Vollenweider, F., et al. (2023). Toward mapping neurobehavioral heterogeneity of psychedelic neurobiology in humans. *Biol. Psychiatry* 93, 1061–1070. doi: 10.1016/j.biopsych.2022.10.021
- Mueller, F., Lenz, C., Dolder, P., Harder, S., Schmid, Y., and Lang, U. (2017). Acute effects of LSD on amygdala activity during processing of fearful stimuli in healthy subjects. *Transl. Psychiatry* 7:e1084. doi: 10.1038/tp.2017.54
- Namasivayam, A., and van Lieshout, P. (2011). Speech motor skill and stuttering. *J. Mot. Behav.* 43, 477–489. doi: 10.1080/00222895.2011.628347
- Nang, C., Hersh, D., Milton, K., and Lau, S. (2018). The impact of stuttering on development of self-identity, relationships, and quality of life in women who stutter. *Am. J. Speech Lang. Pathol.* 27, 1244–1258. doi: 10.1044/2018\_AJSLP-ODC11-17-0201
- Nardou, R., Sawyer, E., Song, Y., Wilkinson, M., Padovan-Hernandez, Y., de Deus, J., et al. (2023). Psychedelics reopen the social reward learning critical period. *Nature* 618, 790–798. doi: 10.1038/s41586-023-06204-3
- Neef, N., Angstadt, M., Koenraads, S., and Chang, S. (2023). Dissecting structural connectivity of the left and right inferior frontal cortex in children who stutter. *Cereb. Cortex* 33, 4085–4100. doi: 10.1093/cercor/bhac328
- Neef, N., Anwander, A., Büttfering, C., Schmidt-Samoa, C., Friederici, A., Paulus, W., et al. (2018a). Structural connectivity of right frontal hyperactive areas scales with stuttering severity. *Brain* 141, 191–204. doi: 10.1093/brain/awx316
- Neef, N., Büttfering, C., Auer, T., Metzger, F., Euler, H., Frahm, J., et al. (2018b). Altered morphology of the nucleus accumbens in persistent developmental stuttering. *J. Fluency Disord.* 55, 84–93. doi: 10.1016/j.jfludis.2017.04.002
- Neef, N., Anwander, A., and Friederici, A. (2015). The neurobiological grounding of persistent stuttering: from structure to function. *Curr. Neurol. Neurosci. Rep.* 15:63. doi: 10.1007/s11910-015-0579-4
- Neef, N., Büttfering, C., Anwander, A., Friederici, A., Paulus, W., and Sommer, M. (2016). Left posterior-dorsal area 44 couples with parietal areas to promote speech fluency, while right area 44 activity promotes the stopping of motor responses. *NeuroImage* 142, 628–644. doi: 10.1016/j.neuroimage.2016.08.030
- Neef, N., and Chang, S. (2024). Knowns and unknowns about the neurobiology of stuttering. *PLoS Biol.* 22:e3002492. doi: 10.1371/journal.pbio.3002492
- Neef, N., Korzeczek, A., Primařin, A., Wolff von Gudenberg, A., Dechent, P., Riedel, C. H., et al. (2022). White matter tract strength correlates with therapy outcome in persistent developmental stuttering. *Hum. Brain Mapp.* 43, 3357–3374. doi: 10.1002/hbm.25853
- Nour, M., Evans, L., Nutt, D., and Carhart-Harris, R. (2016). Ego-dissolution and psychedelics: validation of the ego-dissolution inventory (EDI). *Front. Hum. Neurosci.* 10:269. doi: 10.3389/fnhum.2016.00269
- Nye, C., Vanryckeghem, M., Schwartz, J., Herder, C., Turner, H., and Howard, C. (2013). Behavioral stuttering interventions for children and adolescents: a systematic review and meta-analysis. *J. Speech Lang. Hear. Res.* 56, 921–932. doi: 10.1044/1092-4388(2012)12-0036
- Orpella, J., Flick, G., Assaneo, M., Shroff, R., Pylkkänen, L., Poeppel, D., et al. (2024). Reactive inhibitory control precedes overt stuttering events. *Neurobiol. Lang.* doi: 10.1162/nol\_a\_00138
- Ort, A., Smallridge, J., Sarasso, S., Casarotto, S., von Rotz, R., Casanova, A., et al. (2023). TMS-EEG and resting-state EEG applied to altered states of consciousness: oscillations, complexity, and phenomenology. *iScience* 26:106589. doi: 10.1016/j.isci.2023.106589
- Ozge, A., Toros, F., and Cömelekoglu, U. (2004). The role of hemispherical asymmetry and regional activity of quantitative EEG in children with stuttering. *Child Psychiatry Hum. Dev.* 34, 269–280. doi: 10.1023/B:CHUD.0000020679.15106.a4
- Packman, A. (2012). Theory and therapy in stuttering: a complex relationship. *J. Fluency Disord.* 37, 225–233. doi: 10.1016/j.jfludis.2012.05.004
- Park, V., Onslow, M., Lowe, R., Jones, M., O'Brian, S., Packman, A., et al. (2021). Psychological characteristics of early stuttering. *Int. J. Speech Lang. Pathol.* 23, 622–631. doi: 10.1080/17549507.2021.1912826
- Perkins, W., Kent, R., and Curlee, R. F. A. (1991). theory of neuropsycholinguistic function in stuttering. *J. Speech Hear. Res.* 34, 734–752. doi: 10.1044/jshr.3404.734
- Qureshi, N., Aldossari, A., and Alhabeeb, A. (2021). Speech fluency disorders: a review of studies conducted over the past five decades (1970-2020). *Int. Neuropsychiatric Dis. J.* 15, 1–28. doi: 10.9734/indj/2021/v15i130143
- Raichle, M. (2015). The brain's default mode network. *Annu. Rev. Neurosci.* 38, 433–447. doi: 10.1146/annurev-neuro-071013-014030
- Raichle, M., MacLeod, A., Snyder, A., Powers, W., Gusnard, D., and Shulman, G. L. A. (2001). default mode of brain function. *Proc. Natl. Acad. Sci. U S A.* 98, 676–682. doi: 10.1073/pnas.98.2.676
- Reilly, S., Onslow, M., Packman, A., Wake, M., Bavin, E., Prior, M., et al. (2009). Predicting stuttering onset by the age of 3 years: a prospective, community cohort study. *Pediatrics* 123, 270–277. doi: 10.1542/peds.2007-3219
- Rodgers, N., and Jackson, E. (2021). Temperament is linked to avoidant responses to stuttering anticipation. *J. Commun. Disord.* 93:106139. doi: 10.1016/j.jcomdis.2021.106139
- Roseman, L., Demetriou, L., Wall, M., Nutt, D., and Carhart-Harris, R. (2018). Increased amygdala responses to emotional faces after psilocybin for treatment-resistant depression. *Neuropharmacology* 142, 263–269. doi: 10.1016/j.neuropharm.2017.12.041
- Ross, S., Bossis, A., Guss, J., Agin-Liebes, G., Malone, T., Cohen, B., et al. (2016). Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial. *J. Psychopharmacol.* 30, 1165–1180. doi: 10.1177/0269881116675512
- Rucker, J., and Erritzoe, D. (2023). "Psilocybin" in *Psychedelics as Psychiatric Medications*, eds D. Nutt and D. Castle (Oxford: Oxford University Press). doi: 10.1093/med/9780192863607.003.0003
- Saarelainen, T., Hendolin, P., Lucas, G., Koponen, E., Sairanen, M., MacDonald, E., et al. (2003). Activation of the TrkB neurotrophin receptor is induced by antidepressant drugs and is required for antidepressant-induced behavioral effects. *J. Neurosci.* 23, 349–357. doi: 10.1523/JNEUROSCI.23-01-00349.2003

- Saltuklaroglu, T., Harkrider, A., Thornton, D., Jenson, D., and Kittilstved, T. E. E. G. (2017). Mu (micro) rhythm spectra and oscillatory activity differentiate stuttering from non-stuttering adults. *NeuroImage* 153, 232–245. doi: 10.1016/j.neuroimage.2017.04.022
- Sander, R., and Osborne, C. (2019). Stuttering: understanding and treating a common disability. *Am. Fam. Physician* 100, 556–560.
- Schlag, A., Aday, J., Salam, I., Neill, J., and Nutt, D. (2022). Adverse effects of psychedelics: from anecdotes and misinformation to systematic science. *J. Psychopharmacol.* 36, 258–272. doi: 10.1177/02698811211069100
- Šimić, G., Tkalčić, M., Vukić, V., Mulc, D., Španić, E., Šagud, M., et al. (2021). Understanding emotions: origins and roles of the amygdala. *Biomolecules* 11:823. doi: 10.3390/biom11060823
- Sisskin, V., and Goldstein, B. (2022). Avoidance reduction therapy for school-age children who stutter. *Semin. Speech Lang.* 43, 147–160. doi: 10.1055/s-0042-1742695
- Smigielski, L., Scheidegger, M., Kometer, M., and Vollenweider, F. (2019). Psilocybin-assisted mindfulness training modulates self-consciousness and brain default mode network connectivity with lasting effects. *NeuroImage* 196, 207–215. doi: 10.1016/j.neuroimage.2019.04.009
- Smith, A., and Weber, C. (2017). How stuttering develops: the multifactorial dynamic pathways theory. *J. Speech Lang. Hear. Res.* 60, 2483–2505. doi: 10.1044/2017\_JSLHR-S-16-0343
- Sommer, M., Koch, M., Paulus, W., Weiller, C., and Buchel, C. (2002). Disconnection of speech-relevant brain areas in persistent developmental stuttering. *Lancet* 360, 380–383. doi: 10.1016/S0140-6736(02)09610-1
- Sridharan, D., Levitin, D., and Menon, V. A. (2008). critical role for the right fronto-insular cortex in switching between central-executive and default-mode networks. *Proc. Natl. Acad. Sci. U S A.* 105, 12569–12574. doi: 10.1073/pnas.0800005105
- St Clare, T., Menzies, R., Onslow, M., Packman, A., Thompson, R., and Block, S. (2009). Unhelpful thoughts and beliefs linked to social anxiety in stuttering: development of a measure. *Int. J. Lang. Commun. Disord.* 44, 338–351. doi: 10.1080/13682820802067529
- Tagliazucchi, E., Roseman, L., Kaelen, M., Orban, C., Muthukumaraswamy, S., Murphy, K., et al. (2016). Increased global functional connectivity correlates with LSD-induced ego dissolution. *Curr. Biol.* 26, 1043–1050. doi: 10.1016/j.cub.2016.02.010
- Tendera, A., Wells, R., Belyk, M., Varyvoda, D., Boliek, C., and Beal, D. (2020). Motor sequence learning in children with recovered and persistent developmental stuttering: preliminary findings. *J. Fluency Disord.* 66:105800. doi: 10.1016/j.jfludis.2020.105800
- The Lancet Regional Health - Europe (2023). Psychedelic-assisted psychotherapy: hope and dilemma. *Lancet Regional Health Eur.* 32:100727. doi: 10.1016/j.lanep.2023.100727
- Thorstensen, J., Henderson, T., and Kavanagh, J. (2024). Serotonergic and noradrenergic contributions to motor cortical and spinal motoneuronal excitability in humans. *Neuropharmacology* 242:109761. doi: 10.1016/j.neuropharm.2023.109761
- Tichenor, S., and Yaruss, J. S. (2020). Repetitive negative thinking, temperament, and adverse impact in adults who stutter. *Am. J. Speech Lang. Pathol.* 29, 201–215. doi: 10.1044/2019\_AJSLP-19-00077
- Tichenor, S., and Yaruss, J. (2021). Variability of stuttering: behavior and impact. *Am. J. Speech Lang. Pathol.* 30, 75–88. doi: 10.1044/2020\_AJSLP-20-00112
- Timmermann, C., Roseman, L., Haridas, S., Rosas, F., Luan, L., Kettner, H., et al. (2023). Human brain effects of DMT assessed via EEG-fMRI. *Proc. Natl. Acad. Sci. U S A.* 120:e2218949120. doi: 10.1073/pnas.2218949120
- Toyomura, A., Fujii, T., Yokosawa, K., and Kuriki, S. (2018). Speech disfluency-dependent amygdala activity in adults who stutter: neuroimaging of interpersonal communication in MRI scanner environment. *Neuroscience* 374, 144–154. doi: 10.1016/j.neuroscience.2018.01.037
- Turk, A., Lotfi Marchoubeh, M., Fritsch, I., Maguire, G., and SheikhBahaei, S. (2021). Dopamine, vocalization, and astrocytes. *Brain Lang.* 219:104970. doi: 10.1016/j.bandl.2021.104970
- Vamvakopoulou, I., Narine, K., Campbell, I., Dyck, J., and Nutt, D. (2023). Mescaline: the forgotten psychedelic. *Neuropharmacology* 222:109294. doi: 10.1016/j.neuropharm.2022.109294
- Van Riper, C. (1982). *The Nature of Stuttering*. Englewood Cliffs, NJ: Prentice-Hall.
- Vollenweider, F., Leenders, K., Scharfetter, C., Maguire, P., Stadelmann, O., and Angst, J. (1997). Positron emission tomography and fluorodeoxyglucose studies of metabolic hyperfrontality and psychopathology in the psilocybin model of psychosis. *Neuropsychopharmacology* 16, 357–372. doi: 10.1016/S0893-133X(96)00246-1
- Vollenweider, F., and Preller, K. (2020). Psychedelic drugs: neurobiology and potential for treatment of psychiatric disorders. *Nat. Rev. Neurosci.* 21, 611–624. doi: 10.1038/s41583-020-0367-2
- Walden, T., Frankel, C., Buhr, A., Johnson, K., Conture, E., and Karrass, J. (2012). Dual diathesis-stressor model of emotional and linguistic contributions to developmental stuttering. *J. Abnorm Child Psychol.* 40, 633–644. doi: 10.1007/s10802-011-9581-8
- Wall, M., Harding, R., Zafar, R., Rabiner, E., Nutt, D., and Erritzoe, D. (2023). Neuroimaging in psychedelic drug development: past, present, and future. *Mol. Psychiatry* 28, 3573–3580. doi: 10.1038/s41380-023-02271-0
- Watkins, K., Smith, S., Davis, S., and Howell, P. (2008). Structural and functional abnormalities of the motor system in developmental stuttering. *Brain* 131, 50–59. doi: 10.1093/brain/awm241
- Weber, E., and Andrade, R. (2010). Htr2a gene and 5-HT(2A) receptor expression in the cerebral cortex studied using genetically modified mice. *Front. Neurosci.* 4:36. doi: 10.3389/fnins.2010.00036
- Weber-Fox, C., Wray, A., and Arnold, H. (2013). Early childhood stuttering and electrophysiological indices of language processing. *J. Fluency Disord.* 38, 206–221. doi: 10.1016/j.jfludis.2013.01.001
- Wolff, A., Schumacher, N., Pürner, D., Machetanz, G., Demleitner, A., Feneberg, E., et al. (2023). Parkinson's disease therapy: what lies ahead? *J. Neural Transm.* 130, 793–820. doi: 10.1007/s00702-023-02641-6
- Wu, J., Maguire, G., Riley, G., Fallon, J., LaCasse, L., Chin, S., et al. (1995). A positron emission tomography [18F]deoxyglucose study of developmental stuttering. *Neuroreport* 6, 501–505. doi: 10.1097/00001756-199502000-00024
- Wu, J., Maguire, G., Riley, G., Lee, A., Keator, D., Tang, C., et al. (1997). Increased dopamine activity associated with stuttering. *Neuroreport* 8, 767–770. doi: 10.1097/00001756-199702100-00037
- Wulf, G., McNevin, N., and Shea, C. (2001). The automaticity of complex motor skill learning as a function of attentional focus. *Q. J. Exp. Psychol. A* 54, 1143–1154. doi: 10.1080/713756012
- Xuan, Y., Meng, C., Yang, Y., Zhu, C., Wang, L., Yan, Q., et al. (2012). Resting-state brain activity in adult males who stutter. *PLoS One* 7:e30570. doi: 10.1371/journal.pone.0030570
- Yang, Y., Jia, F., Siok, W., and Tan, L. (2017). The role of anxiety in stuttering: evidence from functional connectivity. *Neuroscience* 346, 216–225. doi: 10.1016/j.neuroscience.2016.11.033